View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 31, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Trading Symbol	CC
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		185,163,064

Interim Consolidated Statements of Operations (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Net sales	$ 1,584	$ 1,398	$ 4,608	$ 4,078
Cost of goods sold	1,117	1,056	3,341	3,267
Gross profit	467	342	1,267	811
Selling, general and administrative expense	148	148	444	454
Research and development expense	20	19	61	60
Restructuring and asset-related charges, net	8	60	31	145
Total expenses	176	227	536	659
Equity in earnings of affiliates	9	9	26	17
Interest expense, net	(55)	(51)	(161)	(157)
Other income, net	5	161	53	250
Income before income taxes	250	234	649	262
Provision for income taxes	43	30	130	25
Net income (loss)	207	204	519	237
Less: Net income attributable to non-controlling interests		0	1	0
Net income (loss) attributable to Chemours	$ 207	$ 204	$ 518	$ 237
Per share data
Basic earnings per share of common stock	$ 1.12	$ 1.12	$ 2.81	$ 1.31
Diluted earnings per share of common stock	1.08	1.11	2.72	1.30
Dividends per share of common stock	$ 0.03	$ 0.03	$ 0.09	$ 0.09

Interim Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income, pre-tax	$ 250	$ 234	$ 649	$ 262
Net Income, tax	(43)	(30)	(130)	(25)
Net income (loss)	207	204	519	237
Other comprehensive income (loss):
Unrealized loss on net investment hedge, pre-tax	(26)	(6)	(76)	(9)
Unrealized loss on net investment hedge, tax	10	0	20	0
Unrealized loss on net investment hedge, after-tax	(16)	(6)	(56)	(9)
Cumulative translation adjustments, pre-tax	35	10	224	20
Cumulative translation adjustments, tax	0	0	0	0
Cumulative translation adjustments, after-tax	35	10	224	20
Defined benefit plans:
Net gain (loss), pre-tax	5	0	5	(7)
Net gain (loss), tax	0	0	0	1
Net gain (loss), after-tax	5	0	5	(6)
Effect of foreign exchange rates, pre-tax	(9)	(3)	(36)	(5)
Effect of foreign exchange rates, tax	2	1	8	2
Effect of foreign exchange rates, after-tax	(7)	(2)	(28)	(3)
Amortization of prior service gain, pre-tax	(1)	0	(1)	(1)
Amortization of prior service gain, tax	0	0	0	0
Amortization of prior service gain, after tax	(1)	0	(1)	(1)
Amortization of actuarial loss, pre-tax	5	6	15	18
Amortization of acturial loss, tax	(1)	(2)	(3)	(5)
Amortization of acturial loss, after tax	4	4	12	13
Settlement loss, pre-tax	1	0	1	(2)
Settlement loss, tax	0	0	0	1
Settlement loss, after tax	1	0	1	(1)
Defined benefit plans, net, pre-tax	1	3	(16)	3
Defined benefit plans, net, tax	1	(1)	5	(1)
Defined benefit plans, net, after-tax	2	2	(11)	2
Other comprehensive income, pre-tax	10	7	132	14
Other comprehensive income, tax	11	(1)	25	(1)
Other comprehensive income, after tax	21	6	157	13
Comprehensive income, pre-tax	260	241	781	276
Comprehensive income, tax	(32)	(31)	(105)	(26)
Comprehensive income, after-tax	228	210	676	250
Less: Comprehensive income attributable to non-controlling interests, pre-tax	0	0	1	0
Less: Comprehensive income attributable to non-controlling interests, tax	0	0	0	0
Less: Comprehensive income attributable to non-controlling interests, after-tax	0	0	1	0
Comprehensive income attributable to Chemours, pre-tax	260	241	780	276
Comprehensive income attributable to Chemours, tax	(32)	(31)	(105)	(26)
Comprehensive income attributable to Chemours, after-tax	$ 228	$ 210	$ 675	$ 250

Interim Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,535	$ 902
Accounts and notes receivable - trade, net	942	807
Inventories	877	767
Prepaid expenses and other	79	77
Total current assets	3,433	2,553
Property, plant and equipment	8,412	7,997
Less: Accumulated depreciation	(5,462)	(5,213)
Property, plant and equipment, net	2,950	2,784
Goodwill and other intangible assets, net	167	170
Investments in affiliates	166	136
Other assets	404	417
Total assets	7,120	6,060
Current liabilities:
Accounts payable	1,010	884
Current maturities of long-term debt	14	15
Other accrued liabilities	546	872
Total current liabilities	1,570	1,771
Long-term debt, net	4,081	3,529
Deferred income taxes	175	132
Other liabilities	489	524
Total liabilities	6,315	5,956
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 185,092,058 and 182,600,533 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively)	2	2
Additional paid-in capital	830	789
Retained earnings (accumulated deficit)	388	(114)
Accumulated other comprehensive loss	(420)	(577)
Total Chemours stockholders’ equity	800	100
Non-controlling interests	5	4
Total equity	805	104
Total liabilities and equity	$ 7,120	$ 6,060

Interim Consolidated Balance Sheet (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, shares authorized (in shares)	810,000,000	810,000,000
Common stock , par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares Issued (in shares)	185,092,058	182,600,533
Common stock, shares outstanding (in shares)	185,092,058	182,600,533

Interim Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit Retained Earnings [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interests [Member]
Total stockholders' equity, beginning balance at Dec. 31, 2015	$ 130	$ 2	$ 775	$ (115)	$ (536)	$ 4
Shares, beginning balance at Dec. 31, 2015		181,069,751
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	237			237
Common stock issued - compensation plans (in shares)		650,971
Dividends	(16)		(11)	(5)
Other comprehensive income	13				13
Stock-based compensation expense	17		17
Total stockholders' equity, ending balance at Sep. 30, 2016	381	$ 2	781	117	(523)	4
Shares, ending balance at Sep. 30, 2016		181,720,722
Total stockholders' equity, beginning balance at Dec. 31, 2016	104	$ 2	789	(114)	(577)	4
Shares, beginning balance at Dec. 31, 2016		182,600,533
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	519			518		1
Common stock issued - compensation plans (in shares)		504,098
Dividends	(16)			(16)
Other comprehensive income	157				157
Stock-based compensation expense	21		21
Cancellation of unissued stock awards withheld to cover taxes	(10)		(10)
Exercise of stock options, net	30		30
Exercise of stock options, net (in shares)		1,987,427
Total stockholders' equity, ending balance at Sep. 30, 2017	$ 805	$ 2	$ 830	$ 388	$ (420)	$ 5
Shares, ending balance at Sep. 30, 2017		185,092,058

Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net income	$ 519	$ 237
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	204	212
Amortization of deferred financing costs and issuance discount	10	15
Gain on sale of assets and businesses	(14)	(258)
Equity in earnings of affiliates	(26)	(17)
Deferred tax provision (benefit)	53	(29)
Asset-related charges	3	109
Other operating charges and credits, net	26	33
(Increase) decrease in operating assets:
Accounts and notes receivable - trade, net	(110)	(63)
Inventories and other operating assets	(91)	113
(Decrease) increase in operating liabilities:
Accounts payable and other operating liabilities	(238)	(28)
Cash provided by operating activities	336	324
Investing activities
Purchases of property, plant and equipment	(246)	(235)
Proceeds from sales of assets and businesses, net	39	707
Foreign exchange contract settlements, net	5	(1)
Investment in affiliates	0	2
Cash (used for) provided by investing activities	(202)	469
Financing activities
Proceeds from issuance of debt, net	494	0
Debt repayments	(24)	(212)
Dividends paid	(16)	(16)
Deferred financing fees	(6)	(2)
Tax payments related to withholdings on vested restricted stock units	(10)	0
Proceeds from exercised stock options, net	30	0
Cash provided by (used for) financing activities	468	(230)
Effect of exchange rate changes on cash and cash equivalents	31	28
Increase in cash and cash equivalents	633	591
Cash and cash equivalents at beginning of the period	902	366
Cash and cash equivalents at end of the period	1,535	957
Non-cash investing activities
Change in property, plant and equipment included in accounts payable	$ (16)	$ 9

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Note 1. Basis of Presentation The accompanying interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States of America (U.S.) for interim financial information. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year and the year-end consolidated balance sheet does not include all disclosures required by U.S. GAAP. As such, these interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which was not material to the interim consolidated financial statements. Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our Company”, “we”, “us” and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries, unless the context otherwise requires.

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Recent Accounting Pronouncements	Note 2. Recent Accounting Pronouncements Accounting Guidance Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” The objective of this standard is to remove inconsistent practices with regard to revenue recognition between U.S. GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with Topic 606. The provisions of ASU No. 2014-09 and its related updates will be effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company will adopt the standard on January 1, 2018 under the modified retrospective transition method. The Company’s project plan includes a three-phase approach to implementing the standard update. Phase one, the assessment phase, was completed in the first quarter of 2017. In this initial phase, the Company (a) conducted internal surveys of its businesses, (b) held revenue recognition workshops with sales and business unit finance leadership and (c) reviewed a representative sample of revenue arrangements across all businesses to initially identify a set of applicable qualitative revenue recognition changes related to the standard. The Company has also completed phase two of the project, which included (a) establishing and documenting key accounting positions, (b) assessing new disclosure requirements, business process and control impacts and (c) beginning to determine the initial quantitative impacts resulting from the standard. Phase three will include (a) finalizing any changes to accounting policies, (b) preparing new disclosures, (c) implementing new business processes and controls as needed and (d) quantifying the effect of adoption on opening retained earnings. Based on the analysis conducted to date, the Company believes that the adoption of the standard will not have a material impact on its consolidated financial statements. Substantially all of the Company’s revenue consists of sales of products that represent a single performance obligation where control transfers at the point in time title and risk of loss pass to the customer. The Company continues to evaluate the impact of the standard update on its consolidated financial statements and related disclosures and additional differences may be identified as new or amended contracts with customers that will impact future periods are executed. The Company expects that disclosure in the notes to the consolidated financial statements related to revenue recognition will be expanded in line with the requirements of the standard to further describe the nature, timing and uncertainty of revenue and cash flows arising from contracts with customers. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents an improvement over previous U.S. GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early application of the amendments in this update is permitted for all entities. At adoption, the Company will recognize a right-of-use asset and a lease liability initially measured at the present value of its operating lease payments. The Company is currently evaluating the other impacts of adopting this guidance on its financial position, results of operations and cash flows. In August 2016, the FASB issued various updates to ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”, which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method (unless impractical to do so) for each period presented and earlier application is permitted. Chemours does not expect that the adoption will have a significant impact on its cash flows. In March 2017, the FASB issued ASU No. 2017-07, “Compensation - Retirement Benefits (Topic 715)”, which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The guidance is effective for public business entities for annual periods beginning after December 15, 2017, as well as interim periods within those annual periods. The amendments in this update should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. Early adoption is permitted within the first interim period of an annual period for which financial statements have not been issued or made available for issuance. Chemours does not expect that the adoption will have a significant impact on its financial position, results of operations or cash flows. In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging (Topic 815)”, which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The guidance is effective for public business entities for fiscal years beginning after December 15, 2018, as well as interim periods within those fiscal years. Early adoption is permitted in any interim period. The amendments in this update should be applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. Chemours is currently evaluating the impact of adopting this guidance on its financial position, results of operations and cash flows. Recently Adopted Accounting Guidance In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718).” The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Chemours adopted this guidance effective January 1, 2017, and the adoption did not have a significant impact on the Company’s financial position, results of operations or cash flows except for the impact of windfall income tax benefits on share-based payments and the classification of employee withholding tax payments on vested restricted stock units (RSUs) as a financing activity on the statements of cash flows. Specific to the impact of windfall tax benefits, the Company expects the guidance will cause volatility in its income tax rates going forward. As of the adoption date, there were no windfall tax benefits from prior periods recognized; therefore, prior period adjustments were not required under a modified retrospective basis. For the three and nine months ended September 30, 2017, Chemours recognized $5 and $18 of windfall tax benefits, respectively, primarily from significant options exercised and RSUs vested, which were included in the provision for income taxes in the consolidated statements of operations. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to determine the fair value of the individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Any impairment charges recognized would not exceed the total amount of goodwill allocated to the reporting unit. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company has adopted this guidance and will implement its provisions for interim and annual goodwill impairment tests performed prospectively. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations or cash flows. In May 2017, the FASB issued ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting”, which provides clarity and reduces both diversity in practice and the cost and complexity of applying the guidance in Topic 718 to a change in the terms or conditions of a share-based payment award. Pursuant to this update, modification accounting is required to be applied to changes in the terms and conditions of a share-based payment award unless all of the following criteria remain unchanged before and after the award is modified: (a) the fair value of the award; (b) the vesting conditions of the award; and (c) the classification of the award as an equity instrument or a liability instrument. The amendments in this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and are to be applied prospectively to an award modified on or after the adoption date. Early adoption, including adoption in any interim period, is permitted for public business entities in reporting periods for which financial statements have not yet been issued. The Company has adopted this guidance and will implement its provisions prospectively for changes in the terms and conditions of share-based payment awards. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations or cash flows.

Restructuring and Asset Related Charges, Net

9 Months Ended

Sep. 30, 2017

Restructuring And Related Activities [Abstract]

Restructuring and Asset Related Charges, Net

Note 3. Restructuring and Asset-Related Charges, Net

For the three and nine months ended September 30, 2017 and 2016, Chemours recorded restructuring and asset-related charges, net as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Restructuring-related charges:
Employee separation charges	$	—	$	1	$	5	$	3
Decommissioning and other charges, net		8		13		26		38
Subtotal		8		14		31		41
Asset-related charges - impairment ¹		—		46		—		104
Total restructuring and asset-related charges, net	$	8	$	60	$	31	$	145

¹	The three and nine months ended September 30, 2016 include an impairment charge of $46 related to the aniline facility in Pascagoula, Mississippi. The nine months ended September 30, 2016 includes an impairment charge of $58 related to the sale of the Sulfur business.

Charges related to the Company’s restructuring programs impacted segment earnings for the three and nine months ended September 30, 2017 and 2016 as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Plant and product line closures¹:
Titanium Technologies	$	—	$	5	$	4	$	24
Fluoroproducts		—		1		3		6
Chemical Solutions		5		7		16		6
Subtotal		5		13		23		36
2015 Global Restructuring:
Titanium Technologies		—		—		—		2
Fluoroproducts		—		1		—		3
Chemical Solutions		—		—		—		—
Subtotal		—		1		—		5
2017 Restructuring Program		3		—		8		—
Total restructuring charges, net	$	8	$	14	$	31	$	41

¹	Includes charges related to employee separation and decommissioning costs in connection with the restructuring activities.

Plant and Product Line Closures

In the Titanium Technologies segment, due to the closure of the Edge Moor, Delaware manufacturing plant in the U.S., the Company recorded decommissioning and dismantling-related charges of $4 for the nine months ended September 30, 2017 and $5 and $24 for the three and nine months ended September 30, 2016, respectively. The Company completed all actions related to these restructuring activities and sold the site during the first quarter of 2017. The cumulative amount incurred, excluding non-cash asset-related charges in connection with the Edge Moor plant closure, was approximately $60.

In the Fluoroproducts segment, the Company recorded additional decommissioning and dismantling-related charges for certain of its production lines in the U.S. of $3 for the nine months ended September 30, 2017 and $1 and $6 for the three and nine months ended September 30, 2016, respectively. As of September 30, 2017, the Company incurred, in the aggregate, approximately $17 of restructuring costs, excluding non-cash asset-related charges. The Company has substantially completed the actions related to these restructuring activities for certain of its Fluoroproducts production lines, which were initiated in 2015.

In the Chemicals Solutions segment, following the production shutdown of the Reactive Metals Solutions (RMS) manufacturing plant at Niagara Falls, New York in September 2016, the Company immediately began decommissioning the plant. As a result, the Company recorded $5 and $16 of decommissioning and dismantling-related charges for the three and nine months ended September 30, 2017, respectively, and $7 and $6 for the three and nine months ended September, 30, 2016, respectively. As of September 30, 2017, the Company incurred, in the aggregate, approximately $30 of restructuring costs, excluding non-cash asset-related charges. Additional restructuring charges of approximately $5 for decommissioning and site redevelopment are expected to be incurred for the remainder of 2017, which will be expensed as incurred.

2017 Restructuring Program

In 2017, the Company announced certain restructuring activities designed to further the cost savings and productivity improvements outlined under management’s transformation plan. These activities include, among other efforts: (a) outsourcing and further centralizing certain business process activities; (b) consolidating existing, outsourced third party information technology (IT) providers; and (c) implementing various upgrades to the Company’s current IT infrastructure. In connection with these corporate function efforts, the Company recorded $3 and $8 in restructuring-related charges for the three and nine months ended September 30, 2017, respectively.

Also, in October 2017, the Company announced a voluntary separation program (VSP) for certain eligible U.S. employees in an effort to better manage anticipated future changes to its workforce. Employees who volunteer for, and are accepted under, the VSP will receive certain financial incentives above the Company’s customary involuntary termination benefits to end their employment with Chemours after providing a mutually agreed-upon service period. Based on current estimates, Chemours anticipates that approximately 300 to 350 employees will separate from the Company by the end of 2018. An accrual representing the majority of these termination benefits will be recognized in the fourth quarter of 2017, and any remaining incremental, one-time financial incentives under the VSP will be recognized over the period each participating employee continues to provide service to Chemours. No amounts for the VSP have been recognized in the consolidated financial statements as of September 30, 2017.

As a result of its 2017 program, the Company expects to incur charges for restructuring-related activities and termination benefits ranging from $45 to $55 through December 31, 2018.

The following table shows the change in the employee separation-related liability account associated with the Company’s restructuring programs:

	Titanium Technologies Site Closures			Fluoro- Products Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			2017 Restructuring Program		Total
Balance at December 31, 2016	$	4		$	1		$	8		$	21		$	—	$	34
Charges to income		—			—			—			—			5		5
Payments		(3	)		(1	)		(4	)		(19	)		—		(27	)
Net currency translation and other adjustments ¹		—			—			—			1			—		1
Balance at September 30, 2017	$	1		$	—		$	4		$	3		$	5	$	13

¹	Amounts include net currency translation adjustment of less than $1 for the periods presented and rounding differences.

At September 30, 2017, there are no significant outstanding liabilities related to decommissioning and other restructuring-related charges.

Other Income, Net

9 Months Ended

Sep. 30, 2017

Other Income And Expenses [Abstract]

Other Income, Net

Note 4. Other Income, Net

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017		2016
Leasing, contract services and miscellaneous income	$	7		$	6		$	24	$	18
Royalty income¹		2			3			12		11
Gain on sale of assets and businesses ²		—			169			14		258
Exchange (losses) gains, net ³		(4	)		(17	)		3		(37	)
Total other income, net	$	5		$	161		$	53	$	250

¹	Royalty income is primarily from technology and trademark licensing.

For the nine months ended September 30, 2017, gain on sale includes a $12 gain associated with the sale of the Edge Moor, Delaware site. For the three and nine months ended September 30, 2016, gain on sale includes gains of $169 and $89 associated with the sale of the Clean & Disinfect product line and the Beaumont, Texas site, respectively.

³	Exchange (losses) gains, net includes gains and losses on foreign currency forward contracts.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 5. Income Taxes For the three months ended September 30, 2017 and 2016, Chemours recorded a provision for income taxes of $43 and $30, respectively, resulting in effective income tax rates of approximately 17% and 13%, respectively. For the nine months ended September 30, 2017 and 2016, Chemours recorded a provision for income taxes of $130 and $25, respectively, resulting in effective income tax rates of approximately 20% and 10%, respectively. The provision for income taxes for the nine months ended September 30, 2017 is inclusive of an $18 benefit from windfalls on share-based payments in accordance with the recently adopted guidance in ASU No. 2016-09, as discussed in Note 2. The remaining change in the effective tax rate from the prior year is primarily due to the Company’s geographical mix of earnings, as well as the impact of the valuation allowance on U.S. foreign tax credits, from which the Company does not expect to benefit in 2017. Each year, Chemours and/or its subsidiaries file income tax returns in U.S. federal and state and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the cognizant taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by Chemours. As a result, income tax uncertainties are recognized in Chemours’ consolidated financial statements in accordance with accounting for income taxes under Topic 740, “Income Taxes”, when applicable. Management is not aware of any other matters that would result in significant changes to the amount of unrecognized income tax benefits reflected in the consolidated balance sheets at September 30, 2017. For the year ended December 31, 2016, the Company established a valuation allowance against its U.S. foreign tax credits. The Company regularly monitors positive and negative evidence that may change the most recent assessment of the Company’s ability to realize a benefit from these deferred tax assets. The Company continues to maintain a valuation allowance against its net deferred tax assets related to U.S. foreign tax credits of $65 and $50 at September 30, 2017 and December 31, 2016, respectively.

Earnings Per Share of Common Stock

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

Note 6. Earnings Per Share of Common Stock

The following table shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Numerator:
Net income attributable to Chemours	$	207	$	204	$	518	$	237
Denominator:
Weighted-average number of common shares outstanding - basic		185,431,036		181,596,161		184,641,599		181,452,194
Dilutive effect of the Company’s employee compensation plans ¹		6,206,778		1,932,395		5,909,015		1,089,738
Weighted-average number of common shares outstanding - diluted ¹		191,637,814		183,528,556		190,550,614		182,541,932

Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The following average number of stock options were anti-dilutive and, therefore, were not included in the diluted earnings per share calculation:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Average number of stock options		954		7,224,473		57,429		7,760,665

Accounts and Notes Receivable - Trade, Net

9 Months Ended

Sep. 30, 2017

Receivables [Abstract]

Accounts and Notes Receivable - Trade, Net

Note 7. Accounts and Notes Receivable - Trade, Net


	September 30, 2017		December 31, 2016
Accounts receivable - trade, net ¹	$	872	$	742
VAT, GST and other taxes ²		49		46
Other receivables ³		21		19
Total accounts and notes receivable - trade, net	$	942	$	807

¹	Accounts receivable - trade, net includes trade notes receivable and is net of allowances of $5 at September 30, 2017 and December 31, 2016. Allowances are equal to the estimated uncollectible amounts.

²	Value Added Tax (VAT) and Goods and Services Tax (GST).

³	Other receivables consist of advances and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than $1 for the three and nine months ended September 30, 2017. Bad debt expense was $7 for the three and nine months ended September 30, 2016.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

9 Months Ended

Sep. 30, 2017

Inventory Net [Abstract]

Inventories

Note 8. Inventories

	September 30, 2017			December 31, 2016
Finished products	$	592		$	532
Semi-finished products		176			150
Raw materials, stores and supplies		309			285
Subtotal		1,077			967
Adjustment of inventories to LIFO basis		(200	)		(200	)
Total inventories	$	877		$	767

Inventory values, before last-in, first-out (LIFO) adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all U.S. locations, which comprised $472 and $465, or 44% and 48%, of inventories before the LIFO adjustments at September 30, 2017 and December 31, 2016, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant and Equipment, Net	9 Months Ended
Property, Plant and Equipment, Net	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Property, Plant and Equipment, Net	Note 9. Property, Plant and Equipment, Net Depreciation expense amounted to $61 and $201 for the three and nine months ended September 30, 2017, respectively, and $72 and $210 for the three and nine months ended September 30, 2016, respectively. Property, plant and equipment, net includes gross assets under capital leases of $5 at September 30, 2017 and December 31, 2016.

Other Assets

9 Months Ended

Sep. 30, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Assets

Note 10. Other Assets

	September 30, 2017		December 31, 2016
Capitalized repair and maintenance costs	$	105	$	145
Pension assets ¹		225		159
Deferred income taxes		38		41
Asset held for sale		—		29
Miscellaneous ²		36		43
Total other assets	$	404	$	417

Pension assets represent the funded status of certain of the Company's long-term employee benefit plans.

Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $10 and $13 at September 30, 2017 and December 31, 2016, respectively, and Company-owned life insurance policies on former key executives of a U.S. subsidiary. The life insurance policies had a cash surrender value of $63 at September 30, 2017 and $61 at December 31, 2016, which are presented net of $63 and $61 in outstanding loans from the policy issuer, respectively.

Asset Held for Sale

In December 2016, in connection with a sale agreement entered in January 2017 to sell the Company’s corporate headquarters building located in Wilmington, Delaware, the Company recorded a $13 pre-tax impairment charge and classified the net book value of the building as an asset held for sale for the year ended December 31, 2016. The Company completed the sale in April 2017 for net proceeds of $29, of which $13 was used to repay a portion of its senior secured term loans. In connection with the sale, Chemours also entered into lease agreements to lease back a portion of the building beginning in April 2017. In connection with the sale and leaseback transaction, the Company deferred a gain of $2 million.

Other Accrued Liabilities

9 Months Ended

Sep. 30, 2017

Payables And Accruals [Abstract]

Other Accrued Liabilities

Note 11. Other Accrued Liabilities

	September 30, 2017		December 31, 2016
Compensation and other employee-related costs	$	147	$	154
Employee separation costs ¹		13		31
Accrued litigation ²		13		344
Environmental remediation ²		86		71
Income taxes		55		39
Customer rebates		70		53
Deferred revenue ³		9		76
Accrued interest		73		21
Miscellaneous ⁴		80		83
Total other accrued liabilities	$	546	$	872

¹	Current portion of employee separation costs.

²	Current portions of accrued litigation and environmental remediation. Accrued litigation includes the PFOA MDL Settlement accrual of $335 at December 31, 2016, which was paid in full by September 30, 2017.

³	Deferred revenue at December 31, 2016 includes $58 in outstanding prepayments by DuPont for specified goods and services. There were no such prepayments at September 30, 2017.

⁴	Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations and other miscellaneous accrued expenses.

Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Debt

Note 12. Debt

	September 30, 2017		December 31, 2016
Senior secured term loans:
Tranche B term loan due May 2022	$	—	$	1,372
Tranche B-1 Dollar Term Loan due May 2022		925		—
Tranche B-1 Euro Term Loan due May 2022 (€395 at September 30, 2017 and €0 at December 31, 2016)		464		—
Senior unsecured notes:
6.625% due May 2023		1,158		1,158
7.000% due May 2025		750		750
6.125% due May 2023 (€295 at September 30, 2017 and December 31, 2016)		346		308
5.375% due May 2027		500		—
Capital lease obligations		3		3
Total debt		4,146		3,591
Less: Unamortized issue discounts		9		5
Less: Unamortized debt issuance costs		42		42
Less: Current maturities of long-term debt		14		15
Total long-term debt, net	$	4,081	$	3,529

Senior Secured Credit Facilities

The credit agreement, as amended, provides for seven-year senior secured term loans and a five-year, $750 senior secured revolving credit facility (Revolving Credit Facility). The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general corporate purposes. No borrowings were outstanding under the Revolving Credit Facility at September 30, 2017 or December 31, 2016; however, Chemours had $102 and $132 in letters of credit issued and outstanding under this facility at September 30, 2017 and December 31, 2016, respectively. The Revolving Credit Facility bears variable interest of a range based on Chemours’ total net leverage ratio between (a) a 0.50% and 1.25% spread for base rate loans and (b) a 1.50% and 2.25% spread for LIBOR loans. The applicable margins were 0.50% for base rate loans and 1.50% for LIBOR loans at September 30, 2017. In addition, the Company is required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility at a rate based on its total net leverage ratio, between 0.20% and 0.35%. At September 30, 2017, commitment fees were assessed at a rate of 0.20% per annum.

On April 3, 2017, the Company completed an amendment (April 2017 Amendment) to its credit agreement which provides for a new class of term loans, denominated in Euros, in an aggregate principal amount of €400 (Euro Term Loan), and a new class of term loans, denominated in U.S. Dollars, in an aggregate principal amount of $940 (Dollar Term Loan, and, collectively with the Euro Term Loan, the New Term Loans). The New Term Loans replaced in full the prior term loan (Prior Term Loan) outstanding as of March 31, 2017. The New Term Loans mature on May 12, 2022, which is the same maturity date of the Prior Term Loan. The Euro Term Loan bears a variable interest rate equal to EURIBOR plus 2.25%, subject to a EURIBOR floor of 0.75%, and the Dollar Term Loan bears a variable interest rate equal to LIBOR plus 2.50%, subject to a LIBOR floor of 0.00%. The April 2017 Amendment also modified certain provisions of the credit agreement, including increasing certain incurrence limits to allow further flexibility for the Company. All other provisions, including financial covenants, remained unchanged. No incremental debt was issued as a result of the April 2017 Amendment, although the Euro Term Loan is subject to remeasurement gains or losses. The Company recorded a $3 loss on debt extinguishment and related amendment fees in the second quarter of 2017. The effective interest rates on the Dollar Term Loan and the Euro Term Loan were approximately 3.74% and 3.00%, respectively, for the quarter ended September 30, 2017.

The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility, as amended, require Chemours not to exceed a maximum senior secured net leverage ratio of: (a) 3.50 to 1.00 each quarter through December 31, 2016; (b) 3.00 to 1.00 through June 30, 2017; and (c) further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours’ and its subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. Chemours was in compliance with its debt covenants at September 30, 2017.

Senior Unsecured Notes

On May 23, 2017, Chemours issued a $500 aggregate principal amount of 5.375% senior unsecured notes due May 2027 (2027 Notes). The 2027 Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year. The Company received proceeds of $489, net of an original issue discount of $5 and underwriting fees and other related expenses of $6, which are deferred and amortized to interest expense using the effective interest method over the term of the 2027 Notes. A portion of the net proceeds from the 2027 Notes was used to pay the $335 accrued for the global settlement of the multi-district PFOA litigation, as discussed in Note 13. The remaining proceeds from the 2027 Notes are available for general corporate purposes. The offering of the 2027 Notes was registered under the Securities Act of 1933, as amended, under a registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on May, 4, 2017.

The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis by each of the existing and future domestic subsidiaries that (a) incurs or guarantees indebtedness under the Senior Secured Credit Facilities or (b) guarantees other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100. The guarantees of the 2027 Notes will rank equally with all other senior indebtedness of the guarantors. The 2027 Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and are senior in right of payment to all of Chemours’ existing and future debt that is by its terms expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes are subordinated to indebtedness under the Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt, and structurally subordinated to the liabilities of any non-guarantor subsidiaries.

Chemours may redeem the 2027 Notes, in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified “make-whole” premium and accrued and unpaid interest, if any, to the date of purchase prior to February 15, 2027. Chemours may also redeem some or all of the 2027 Notes by means other than a redemption, including tender offer and open market repurchases. Chemours is obligated to offer to purchase the 2027 Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events.

Maturities

Chemours has required quarterly principal payments related to the senior secured term loans equivalent to 1.00% per annum through March 2022, with the balance due at maturity. Term loan principal maturities, as amended, over the next five years are $3 for the remainder of 2017 and approximately $14 in each year from 2018 to 2021. Debt maturities related to the New Term Loans and the Notes (collectively, the 2023 Notes, the 2025 Notes, the Euro Notes and the 2027 Notes) in 2022 and beyond will be $4,085.

Following the end of each fiscal year commencing on the year ended December 31, 2016, on an annual basis, the Company is also required to make additional principal repayments, depending on leverage levels as defined in the credit agreement, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases to below a 3.00 to 1.00 leverage target. No principal repayments were required to be made in 2017 based upon the December 31, 2016 excess cash flow determined under the credit agreement.

Debt Fair Value

The fair values of the Dollar Term Loan, the Euro Term Loan, the 2023 Notes, the 2025 Notes, the Euro Notes and the 2027 Notes at September 30, 2017 were approximately $931, $469, $1,235, $834, $372 and $520, respectively. The estimated fair values of the New Term Loans and the Notes are based on quotes received from third party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy.

Commitments and Contingent Liabilities

9 Months Ended

Sep. 30, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

Note 13. Commitments and Contingent Liabilities

Litigation

In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to or required under the separation-related agreements executed prior to the separation to indemnify DuPont against various pending legal proceedings arising out of the normal course of Chemours’ business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcomes of these various proceedings. Except for the litigation specific to PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) and Fayetteville, North Carolina for which separate assessments are provided below, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours’ consolidated financial position, results of operations or liquidity. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

(a)

Asbestos

In the separation, DuPont assigned its asbestos docket to Chemours. At September 30, 2017 and December 31, 2016, there were approximately 1,600 and 1,900 lawsuits pending, respectively, against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside the U.S. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees or household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products.

At September 30, 2017 and December 31, 2016, Chemours had an accrual of $41 related to this matter. Chemours reviews this estimate and related assumptions quarterly. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter.

(b)

Benzene

In the separation, DuPont assigned its benzene docket to Chemours. As of September 30, 2017 and December 31, 2016, there were 20 and 27 cases pending against DuPont alleging benzene-related illnesses, respectively. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products such as paints, thinners and reducers.

A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood’s Acute Myelogenous Leukemia was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the plaintiffs’ favor, awarding $6.9 in compensatory damages and $1.5 in punitive damages. In March 2016, acting on the Company’s motion, the court struck the punitive award. Through DuPont, Chemours has filed an appeal on the remaining award based upon substantial errors made at the trial court level. Plaintiffs have filed a cross appeal.

Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure and other factors, a range of such losses cannot be reasonably estimated at this time.

(c)

PFOA

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made PFOA at its Fayetteville, North Carolina plant and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and Shimizu, Japan. These sites are now owned and/or operated by Chemours.

Chemours recorded accruals of $15 and $349 related to the PFOA matters discussed below at September 30, 2017 and December 31, 2016, respectively. Specific to the PFOA MDL Settlement (also discussed below), the Company recorded an accrual of $335 at December 31, 2016, which was paid in installments of $15 and $320 during the second and third quarters of 2017, respectively.

These accruals also include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain Company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory. A provisional health advisory level was set by the EPA in 2009 at 0.4 parts per billion (ppb) that includes PFOA in drinking water. In May 2016, the EPA announced a health advisory level of 0.07 ppb that includes PFOA in drinking water. As a result, Chemours recorded an additional $4 in the second quarter of 2016 based on management’s best estimate of the impact of the new health advisory level on the Company’s obligations to the EPA, which have expanded the testing and water supply commitments previously established. Based on prior testing, the Company has initiated additional testing and treatment in certain additional locations in and around the Chambers Works and Washington Works plants. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

Drinking Water Actions

In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. DuPont funded a series of health studies which were completed in October 2012 by an independent science panel of experts (C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol.

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. DuPont is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing is ongoing and associated payments to service providers are being disbursed from the escrow account. As of September 30, 2017, less than $1 has been disbursed from the escrow account related to medical monitoring. While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the Leach settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At separation, this obligation was assigned to Chemours, which is included in the accrual amounts recorded as of September 30, 2017.

Under the Leach settlement, class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation (MDL) in Ohio federal court.

Settlement of MDL between DuPont and MDL Plaintiffs

In March 2017, DuPont entered into an agreement with the MDL plaintiffs’ counsel providing for a global settlement of all cases and claims in the MDL, including all filed and unfiled personal injury cases and claims that are part of the plaintiffs’ counsel’s claim inventory, as well as cases that have been tried to a jury verdict (MDL Settlement). The total settlement amount is $670.7 in cash, with half paid by Chemours and half paid by DuPont. DuPont’s payment was not subject to indemnification or reimbursement by Chemours, and Chemours accrued $335 associated with this matter at December 31, 2016. In exchange for payment of the total settlement amount, DuPont and Chemours received a complete release of all claims by the settling plaintiffs. As described below, the settling plaintiffs include all but approximately 10 of the plaintiffs who filed cases in the MDL. The MDL Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours. As of September 30, 2017, Chemours has paid the full $335 accrued under the MDL Settlement.

Settlement between DuPont and Chemours Related to MDL

DuPont and Chemours agreed to a limited sharing of potential future PFOA costs (indemnifiable losses, as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours will annually pay future PFOA costs up to $25 and, if such amount is exceeded, DuPont will pay any excess amount up to the next $25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms of the separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties or attorneys’ fees, and waives any such defenses with respect to PFOA costs. Chemours has, however, retained other defenses, including as to whether any particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.

Post-MDL Settlement Injury Matters

There are approximately 10 plaintiffs who declined to participate in the MDL Settlement. Counsel representing most of these plaintiffs have filed motions to withdraw their representation.

The MDL Settlement does not resolve PFOA personal-injury claims of plaintiffs who did not have cases or claims in the MDL or personal-injury claims based on diseases first diagnosed after February 11, 2017. Since the resolution of the MDL, three personal-injury cases have been filed in West Virginia courts.

Management believes that the probability of loss is reasonably possible but not estimable at this time due to various reasons including, among others, that the proceedings are in early stages and there are significant factual issues to be resolved.

Centre Water

In May 2017, the Water Works and Sewer Board of the Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia and suppliers and former suppliers, including DuPont, in Alabama state court. The complaint alleges negligence, nuisance and trespass in the release of perfluorinated compounds, including PFOA, into a river leading to the town’s water source, and seeks compensatory and punitive damages. Management believes that the probability of loss is remote.

PFOA Summary

Chemours accrued $335 associated with the MDL Settlement at December 31, 2016, of which all $335 has been paid through September 30, 2017. There could be additional lawsuits filed related to DuPont’s use of PFOA, its manufacture of PFOA or its customers’ use of DuPont products that may not be within the scope of the MDL Settlement. Any such litigation could result in Chemours incurring additional costs and liabilities. Management believes it is reasonably possible that the Company could incur losses related to other PFOA matters in excess of amounts accrued, but any such losses are not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

(d)

U.S. Smelter and Lead Refinery, Inc.

Six lawsuits, including one putative class action, are pending against DuPont by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Five of the lawsuits allege that Chemours is now responsible for DuPont environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution and damages under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund). At separation, DuPont assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. DuPont has requested that Chemours defend and indemnify it, and Chemours has agreed to do so under a reservation of rights. Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

(e)

Fayetteville, North Carolina

As reported in the press and noted in public statements by the Company, governmental agencies and local community members have made inquiries and engaged in discussions with the Company with respect to the discharge of the polymerization processing aid HFPO Dimer Acid (sometimes referred to as GenX or C3 Dimer) and perfluorinated and polyfluorinated compounds from the Company’s facility in Fayetteville, North Carolina into the Cape Fear River, groundwater and air. The Company believes that such discharges have not impacted the safety of drinking water in North Carolina. Nevertheless, to address community concerns, the Company has voluntarily commenced capturing and separately disposing certain process wastewater from the Fayetteville facility. The Company is also cooperating with a variety of ongoing inquiries and investigations from federal, state and local authorities, regulators and other governmental entities, including responding to two federal grand jury subpoenas.

On September 5, 2017, the North Carolina Department of Environmental Quality (NC DEQ) issued a 60-day notice of intent to suspend the permit for the Fayetteville facility and the State of North Carolina filed an action in North Carolina state court regarding the discharges seeking a temporary restraining order and preliminary injunction, as well as other relief including abatement and site correction. On September 8, 2017, a partial consent order was entered partially resolving the State’s action in return for the Company’s agreement to continue and supplement the voluntary wastewater-disposal measures it had previously commenced and to provide certain information. On October 24, 2017, NC DEQ informed the Company that, based on measures taken by the Company following September 5, 2017, it has concluded at the present time, that it is not necessary to suspend the permit for the Fayetteville facility. The Company is continuing to cooperate with and discuss these matters with the State and NC DEQ.

A number of additional actions have been filed against the Company and DuPont in North Carolina federal court relating to discharges from the Fayetteville site, including an action brought by the Cape Fear Public Utility Authority and one brought by Brunswick County, both seeking damages and injunctive relief, and multiple purported class actions seeking medical monitoring and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River. It is also possible that additional litigation may be filed against the Company and/or DuPont concerning the discharges. The Company believes it has valid defenses to such litigation including that the discharges did not impact the safety of drinking water or cause any damages or injury.

As these issues are in their early stages, however, it is not possible at this point to predict the timing, course or outcome of the governmental and regulatory inquiries, the notice issued by NC DEQ, the action brought by North Carolina and the other litigation, and it is possible that these matters could materially affect the Company’s results and operations. In addition, local communities, organizations and regulatory agencies have raised questions concerning HFPO Dimer Acid at certain other manufacturing sites operated by the Company, and it is possible that similar developments to those described above and centering on the Fayetteville site could arise in other locations.

Environmental

Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Much of this liability results from CERCLA, the Resource Conservation and Recovery Act and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

At September 30, 2017 and December 31, 2016, the consolidated balance sheets included a liability relating to these matters of $268 and $278, respectively, which, in management’s opinion, is appropriate based on existing facts and circumstances. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of ongoing maintenance and monitoring (OM&M) activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $510 above the amount accrued at September 30, 2017.

For the nine months ended September 30, 2017 and 2016, Chemours incurred environmental remediation expenses of $36 and $16, respectively.

Based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the Company’s financial position, results of operations or cash flows in any given year, as such obligation can be satisfied or settled over many years.

Financial Instruments

9 Months Ended

Sep. 30, 2017

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Financial Instruments

Note 14. Financial Instruments

Derivative Instruments

Foreign Currency Forward Contracts

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis on its consolidated balance sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occurred.

At September 30, 2017, there were 26 foreign currency forward contracts outstanding with an aggregate gross notional value of $619. Chemours recognized in other income, net of the consolidated statements of operations, a net loss of $1 and a net gain of $6 for the three and nine months ended September 30, 2017, respectively, and net losses of $2 for the three and nine months ended September 30, 2016.

Net Investment Hedge - Foreign Currency Borrowings

Chemours designated its Euro Notes and, beginning in April 2017, also designated its new Euro Term Loan as a hedge of its net investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours uses the spot method to measure the effectiveness of its net investment hedge. For each reporting period, the change in the carrying value of the Euro Notes and the Euro Term Loan due to remeasurement of the effective portion are reported in accumulated other comprehensive loss on the consolidated balance sheets, and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the consolidated statements of operations. Chemours evaluates the effectiveness of its net investment hedge quarterly. Chemours did not record any ineffectiveness for the three and nine months ended September 30, 2017 or 2016. The Company recognized pre-tax losses of $26 and $76 on its net investment hedges for the three and nine months ended September 30, 2017, respectively. The Company recognized pre-tax losses of $6 and $9 on its net investment hedges for the three and nine months ended September 30, 2016, respectively.

Fair Value of Derivative Instruments

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy:

		Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2017		December 31, 2016
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	3	$	2
Total asset derivatives		$	3	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	4
Total liability derivatives		$	4	$	4

The Company’s foreign currency forward contracts are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance/quality checks.

Long-term Employee Benefits

9 Months Ended

Sep. 30, 2017

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Long-term Employee Benefits

Note 15. Long-term Employee Benefits

The net periodic pension income is based on estimated values and an extensive use of assumptions about the discount rate, expected return on plan assets and the rate of future compensation increases received by the Company's employees.

The components of net periodic pension income for all significant pension plans were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net periodic pension cost (income):
Service cost	$	4		$	3		$	11		$	10
Interest cost		4			5			11			15
Expected return on plan assets		(18	)		(16	)		(52	)		(49	)
Amortization of actuarial loss		5			9			15			20
Amortization of prior service gain		(1	)		—			(1	)		(1	)
Curtailment gain		—			—			—			(2	)
Settlement loss		1			—			1			—
Net periodic pension (income) cost	$	(5	)	$	1		$	(15	)	$	(7	)

The Company made cash contributions of $4 and $14 to its pension plans during the three and nine months ended September 30, 2017 and expects to make additional cash contributions of $11 to its pension plans during the fourth quarter of 2017. Of these remaining contributions, $10 relates to the settlement of the U.S. Pension Restoration Plan (U.S. PRP), which was a supplemental pension plan for certain U.S. employees. The liability associated with the U.S PRP was transferred to Chemours from DuPont at the date of separation, at which point the plan ceased accepting new participants. In October 2017, the Company made a cash payment of $10 to settle the remaining liability attributable to the remaining participants in the U.S. PRP.

Stock-based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-based Compensation

Note 16. Stock-based Compensation

Total stock-based compensation cost included in the consolidated statements of operations was $6 and $21 for the three and nine months ended September 30, 2017, respectively, and $6 and $17 for the three and nine months ended September 30, 2016, respectively. The income tax provision for the three and nine months ended September 30, 2017 is inclusive of $5 and $18 in income tax benefit from windfalls on share-based payments, respectively, due to the Company’s adoption of ASU No. 2016-09 during 2017.

The Chemours Company 2017 Equity and Incentive Plan (2017 Plan) and The Chemours Company Equity and Incentive Plan (Prior Plan) provide for grants to certain employees, independent contractors or non-employee directors of the Company of different forms of awards, including stock options, RSUs and performance share units (PSUs). On April 26, 2017, Chemours’ stockholders approved the 2017 Plan. As a result, no further grants will be made under the Prior Plan, which provided for DuPont equity awards that converted into new Chemours equity awards at the separation date and had a maximum shares reserve of 13,500,000 for the grant of equity awards.

A total of 19,000,000 shares of the Company’s common stock may be subject to awards granted under the 2017 Plan, less one share for every one share that was subject to an option or stock appreciation right granted after December 31, 2016 under the Prior Plan, and one-and-a-half shares for every one share that was subject to an award other than an option or stock appreciation right granted after December 31, 2016 under the Prior Plan. Any shares that are subject to options or stock appreciation rights will be counted against this limit as one share for every one share granted, and any shares that are subject to awards other than options or stock appreciation rights will be counted against this limit as one-and-a-half shares for every one share granted. Awards that were outstanding under the Prior Plan remain outstanding under the Prior Plan in accordance with their terms. Shares underlying awards granted under the Prior Plan after December 31, 2016 that are forfeited, cancelled or that otherwise do not result in the issuance of shares, will be available for issuance under the 2017 Plan. At September 30, 2017, 17,650,034 shares of equity and incentive plan reserve are available for grants under the 2017 Plan.

The Chemours Compensation Committee determines the long-term incentive mix, including stock options, RSUs and PSUs, and may authorize new grants annually.

Stock Options

Chemours granted non-qualified options to certain of its employees, which will serially vest over a three-year period and expire 10 years from the date of grant. The expense related to stock options granted in the nine months ended September 30, 2017 was based on the weighted-average assumptions shown in the table below:

	Nine Months Ended September 30, 2017
Risk-free interest rate		2.14	%
Expected term (years)		6.00
Volatility		44.49	%
Dividend yield		0.35	%
Fair value per stock option	$	15.21

The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on the average volatility of peer companies adjusted for the Company’s debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. Expected life is determined using a simplified approach, calculated as the midpoint between the graded vesting period and the contractual life of the award.

The following table summarizes Chemours’ stock option activity for the nine months ended September 30, 2017:

	Number of Shares (in thousands)			Weighted-Average Exercise Price (per share)		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Granted		878			34.84
Exercised		(1,987	)		14.41
Forfeited		(40	)		19.10
Expired		(28	)		12.00
Outstanding, September 30, 2017		6,792		$	15.69		5.27	$	237,179
Exercisable, September 30, 2017		3,814		$	14.03		3.63	$	139,523

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day at the end of the quarter and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter-end. The amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised for the nine months ended September 30, 2017 was $42. The total intrinsic value of options exercised for the nine months ended September 30, 2016 was insignificant.

At September 30, 2017, $8 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 2.18 years.

RSUs

Chemours granted RSUs to key management employees that generally vest over a three-year period and, upon vesting, convert one-for-one to Chemours’ common stock. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs primarily include awards without a performance condition, as well as a small subset of awards for which specific levels of cost savings and revenue enhancements must be achieved for vesting to occur. Non-vested awards, both with and without a performance condition, at September 30, 2017 are shown below:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		2,316		$	11.23
Granted		211			36.42
Vested		(1,275	)		11.09
Forfeited		(39	)		15.10
Non-vested, September 30, 2017		1,213		$	15.46

At September 30, 2017, there was $7 of unrecognized stock-based compensation expense related to non-vested awards, which is expected to be recognized over a weighted-average period of 0.78 years.

PSUs

Chemours issued PSUs to key senior management employees which, upon vesting, convert one-for-one to Chemours’ common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against stated performance goals. The Company recorded stock-based compensation related to PSUs as a component of selling, general and administrative expense of approximately $2 and $5 for the three and nine months ended September 30, 2017, respectively, and less than $1 and $1 for the three and nine months ended September 30, 2016, respectively.

The following table provides compensation costs for stock-based compensation related to PSUs at 100% of target amounts:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		803		$	6.10
Granted		211			40.30
Vested		—			—
Forfeited		(27	)		16.62
Non-vested, September 30, 2017		987		$	12.94

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted-average fair value at the date of grant for PSUs granted during the three and nine months ended September 30, 2017 was $55.02 and $40.30, respectively. The fair value of each PSU grant is amortized monthly into compensation expense based on their respective vesting conditions over three annual measurement periods. The accrual of compensation costs is based on our estimate of the final expected value of the award, and is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

At September 30, 2017, based on the Company’s assessment of its performance goals for 2016 and 2017, approximately 450,000 additional shares may be awarded under the 2016 and 2017 grant awards.

Employee Stock Purchase Plan

On January 26, 2017, the Company’s board of directors approved The Chemours Company Employee Stock Purchase Plan (ESPP), which was approved by Chemours’ stockholders on April 26, 2017. Under the ESPP, a total of 7,000,000 shares of Chemours’ common stock are reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with four purchase periods beginning and ending on the calendar quarters within those offering periods. The initial offering period under the ESPP began on October 2, 2017. Participating employees will be eligible to purchase the Company’s common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period.

Segment Information

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment Information

Note 17. Segment Information

Chemours’ operations are classified into three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution and regulatory environments. Chemours’ reportable segments are: Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not allocated to the reportable segments and foreign exchange gains and losses are reflected in Corporate and Other.

Segment sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on research and development facilities and amortization of other intangible assets, excluding write-down of assets.

Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) is the primary measure of segment profitability used by the Chief Operating Decision Maker and is defined as income (loss) before income taxes excluding the following:

•

interest expense, depreciation and amortization;

•

non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding service cost component;

•

exchange (gains) losses included in other income (expense), net;

•

restructuring, asset-related charges and other charges, net;

•

asset impairments;

•

(gains) losses on sale of business or assets; and

•

other items not considered indicative of the Company’s ongoing operational performance and expected to occur infrequently.

Three Months Ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	799	$	637	$	148	$	—		$	1,584
Adjusted EBITDA		249		158		18		(44	)		381
Depreciation and amortization		24		28		4		6			62

2016
Net sales to external customers	$	625	$	591	$	182	$	—		$	1,398
Adjusted EBITDA		144		143		9		(28	)		268
Depreciation and amortization		32		26		6		9			73

Nine Months Ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	2,173	$	1,998	$	437	$	—		$	4,608
Adjusted EBITDA		601		510		37		(120	)		1,028
Depreciation and amortization		89		81		13		21			204

2016
Net sales to external customers	$	1,742	$	1,695	$	641	$	—		$	4,078
Adjusted EBITDA		309		333		30		(89	)		583
Depreciation and amortization		87		75		24		26			212

The following is a tabular reconciliation of consolidated income before income taxes to Adjusted EBITDA:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Income before income taxes	$	250		$	234		$	649		$	262
Interest expense, net		55			51			161			157
Depreciation and amortization		62			73			204			212
Non-operating pension and other post-retirement employee benefit income		(7	)		(5	)		(24	)		(19	)
Exchange losses (gains)		4			17			(3	)		37
Restructuring charges		8			14			31			41
Asset-related charges		1			46			3			109
Gain on sale of assets and businesses		—			(169	)		(14	)		(258	)
Transaction costs ¹		1			2			3			18
Legal and other charges ²		7			5			18			24
Adjusted EBITDA	$	381		$	268		$	1,028		$	583

¹	Includes accounting, legal and bankers’ transaction fees incurred related to the Company's strategic initiatives.

²	Includes litigation settlements, water treatment accruals related to PFOA, employee separation costs and lease termination charges.

Guarantor Condensed Consolidating Financial Information

9 Months Ended

Sep. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Guarantor Condensed Consolidating Financial Information

Note 18. Guarantor Condensed Consolidating Financial Information

The following guarantor financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10) in connection with the issuance of the Notes by The Chemours Company (Parent Issuer). The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, in each case, subject to certain exceptions, by the Parent Issuer and by certain subsidiaries (together, Guarantor Subsidiaries). Each of the Guarantor Subsidiaries is 100% owned by the Company. No other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, Non-Guarantor Subsidiaries). The Guarantor Subsidiaries may be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10:

•

the condensed consolidating statements of comprehensive income for the three and nine months ended September 30, 2017 and 2016;

•

the condensed consolidating balance sheets as of September 30, 2017 and December 31, 2016; and

•

the condensed consolidating statements of cash flows for the nine months ended September 30, 2017 and 2016.

The condensed consolidating financial information is presented using the equity method of accounting for the Company’s investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for Chemours’ share of the subsidiaries’ cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the consolidated financial statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.

Condensed Consolidating Statements of Comprehensive Income

	Three Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	960	$	1,053		$	(429	)	$	1,584
Cost of goods sold		—			773		753			(409	)		1,117
Gross profit		—			187		300			(20	)		467
Selling, general and administrative expense		7			105		43			(7	)		148
Research and development expense		—			19		1			—			20
Restructuring and asset-related charges, net		—			8		—			—			8
Total expenses		7			132		44			(7	)		176
Equity in earnings of affiliates		—			—		9			—			9
Equity in earnings of subsidiaries		233			—		—			(233	)		—
Interest (expense) income, net		(57	)		2		—			—			(55	)
Intercompany interest income (expense), net		16			—		(16	)		—			—
Other income (expense), net		6			22		(17	)		(6	)		5
Income before income taxes		191			79		232			(252	)		250
(Benefit from) provision for income taxes		(16	)		18		42			(1	)		43
Net income		207			61		190			(251	)		207
Less: Net income attributable to non-controlling interests		—			—		—			—			—
Net income attributable to Chemours	$	207		$	61	$	190		$	(251	)	$	207
Comprehensive income attributable to Chemours	$	228		$	63	$	225		$	(288	)	$	228

	Three Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	961		$	847		$	(410	)	$	1,398
Cost of goods sold		—			791			656			(391	)		1,056
Gross profit		—			170			191			(19	)		342
Selling, general and administrative expense		5			115			34			(6	)		148
Research and development expense		—			19			—			—			19
Restructuring and asset-related charges, net		—			60			—			—			60
Total expenses		5			194			34			(6	)		227
Equity in earnings of affiliates		—			1			8			—			9
Equity in earnings of subsidiaries		226			—			—			(226	)		—
Interest expense, net		(50	)		(1	)		—			—			(51	)
Intercompany interest income (expense), net		15			1			(16	)		—			—
Other income, net		5			70			94			(8	)		161
Income before income taxes		191			47			243			(247	)		234
(Benefit from) provision for income taxes		(13	)		29			29			(15	)		30
Net income		204			18			214			(232	)		204
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income attributable to Chemours	$	204		$	18		$	214		$	(232	)	$	204
Comprehensive income attributable to Chemours	$	210		$	18		$	226		$	(244	)	$	210

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,904	$	2,941		$	(1,237	)	$	4,608
Cost of goods sold		—			2,358		2,210			(1,227	)		3,341
Gross profit		—			546		731			(10	)		1,267
Selling, general and administrative expense		26			339		101			(22	)		444
Research and development expense		—			57		4			—			61
Restructuring and asset-related charges, net		—			28		3			—			31
Total expenses		26			424		108			(22	)		536
Equity in earnings of affiliates		—			—		26			—			26
Equity in earnings of subsidiaries		594			—		—			(594	)		—
Interest (expense) income, net		(164	)		1		2			—			(161	)
Intercompany interest income (expense), net		48			—		(48	)		—			—
Other income (expense), net		19			93		(37	)		(22	)		53
Income before income taxes		471			216		566			(604	)		649
(Benefit from) provision for income taxes		(47	)		40		136			1			130
Net income		518			176		430			(605	)		519
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	518		$	176	$	429		$	(605	)	$	518
Comprehensive income attributable to Chemours	$	675		$	178	$	640		$	(818	)	$	675

	Nine Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,898		$	2,367		$	(1,187	)	$	4,078
Cost of goods sold		—			2,506			1,921			(1,160	)		3,267
Gross profit		—			392			446			(27	)		811
Selling, general and administrative expense		17			350			103			(16	)		454
Research and development expense		—			58			2			—			60
Restructuring and asset-related charges (credits), net		—			147			(2	)		—			145
Total expenses		17			555			103			(16	)		659
Equity in (loss) earnings of affiliates		—			(2	)		19			—			17
Equity in earnings of subsidiaries		307			—			—			(307	)		—
Interest expense, net		(155	)		(2	)		—			—			(157	)
Intercompany interest income (expense), net		44			4			(48	)		—			—
Other income, net		15			178			72			(15	)		250
Income before income taxes		194			15			386			(333	)		262
(Benefit from) provision for income taxes		(43	)		25			53			(10	)		25
Net income (loss)		237			(10	)		333			(323	)		237
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	237		$	(10	)	$	333		$	(323	)	$	237
Comprehensive income (loss) attributable to Chemours	$	250		$	(10	)	$	355		$	(345	)	$	250

Condensed Consolidating Balance Sheets

	September 30, 2017
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	504		$	1,031		$	—		$	1,535
Accounts and notes receivable - trade, net		—		316			626			—			942
Intercompany receivable		19		684			196			(899	)		—
Inventories		—		348			592			(63	)		877
Prepaid expenses and other		—		59			20			—			79
Deferred income taxes		—		—			—			—			—
Total current assets		19		1,911			2,465			(962	)		3,433
Property, plant and equipment		—		6,346			2,066			—			8,412
Less: Accumulated depreciation		—		(4,410	)		(1,052	)		—			(5,462	)
Property, plant and equipment, net		—		1,936			1,014			—			2,950
Goodwill and other intangible assets, net		—		153			14			—			167
Investments in affiliates		—		—			166			—			166
Investment in subsidiaries		4,114		—			—			(4,114	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		35		101			292			(24	)		404
Total assets	$	5,318	$	4,101		$	3,951		$	(6,250	)	$	7,120
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	589		$	421		$	—		$	1,010
Current maturities of long-term debt		14		—			—			—			14
Intercompany payable		354		196			349			(899	)		—
Other accrued liabilities		72		310			164			—			546
Total current liabilities		440		1,095			934			(899	)		1,570
Long-term debt, net		4,078		3			—			—			4,081
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		107			92			(24	)		175
Other liabilities		—		392			97			—			489
Total liabilities		4,518		1,597			2,273			(2,073	)		6,315
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		800		2,504			1,673			(4,177	)		800
Non-controlling interests		—		—			5			—			5
Total equity		800		2,504			1,678			(4,177	)		805
Total liabilities and equity	$	5,318	$	4,101		$	3,951		$	(6,250	)	$	7,120

Condensed Consolidating Balance Sheets

	December 31, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	224		$	678		$	—		$	902
Accounts and notes receivable - trade, net		—		299			508			—			807
Intercompany receivable		3		1,050			46			(1,099	)		—
Inventories		—		341			476			(50	)		767
Prepaid expenses and other		—		38			32			7			77
Total current assets		3		1,952			1,740			(1,142	)		2,553
Property, plant and equipment, net		—		6,136			1,861			—			7,997
Less: Accumulated depreciation		—		(4,285	)		(928	)		—			(5,213	)
Property, plant and equipment, net		—		1,851			933			—			2,784
Goodwill and other intangible assets, net		—		156			14			—			170
Investments in affiliates		—		—			136			—			136
Investment in subsidiaries		3,258		—			—			(3,258	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		13		178			226			—			417
Total assets	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	573		$	311		$	—		$	884
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		762		46			291			(1,099	)		—
Other accrued liabilities		21		718			133			—			872
Total current liabilities		798		1,337			735			(1,099	)		1,771
Long-term debt, net		3,526		3			—			—			3,529
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		59			73			—			132
Other liabilities		—		428			96			—			524
Total liabilities		4,324		1,827			2,054			(2,249	)		5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		100		2,310			991			(3,301	)		100
Non-controlling interests		—		—			4			—			4
Total equity		100		2,310			995			(3,301	)		104
Total liabilities and equity	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060

Condensed Consolidating Statements of Cash Flows

	Nine Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(60	)	$	32		$	364		$	—		$	336
Investing activities
Purchases of property, plant and equipment		—			(204	)		(42	)		—			(246	)
Proceeds from sales of assets and businesses, net		—			39			—			—			39
Intercompany investing activities		—			408			—			(408	)		—
Foreign exchange contract settlements, net		—			5			—			—			5
Cash provided by (used for) investing activities		—			248			(42	)		(408	)		(202	)
Financing activities
Proceeds from the issuance of debt, net		494			—			—			—			494
Intercompany short-term borrowing repayments, net		(408	)		—			—			408			—
Debt repayments		(24	)		—			—			—			(24	)
Dividends paid		(16	)		—			—			—			(16	)
Debt issuance costs		(6	)		—			—			—			(6	)
Tax payments related to withholdings on vested restricted stock units		(10	)		—			—			—			(10	)
Proceeds from issuance of stock options, net		30			—			—			—			30
Cash provided by financing activities		60			—			—			408			468
Effect of exchange rate changes on cash and cash equivalents		—			—			31			—			31
Increase in cash and cash equivalents		—			280			353			—			633
Cash and cash equivalents at beginning of the period		—			224			678			—			902
Cash and cash equivalents at end of the period	$	—		$	504		$	1,031		$	—		$	1,535

Condensed Consolidating Statements of Cash Flows

	Nine Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(105	)	$	173		$	256		$	—		$	324
Investing activities
Purchases of property, plant and equipment		—			(142	)		(93	)		—			(235	)
Proceeds from sales of assets and businesses, net		—			590			117			—			707
Intercompany investing activities		—			(328	)		—			328			—
Foreign exchange contract settlements		—			(1	)		—			—			(1	)
Investment in affiliates		—			—			(2	)		—			(2	)
Cash provided by investing activities		—			119			22			328			469
Financing activities
Intercompany short-term borrowings, net		328			—			—			(328	)		—
Debt repayments		(205	)		(7	)		—			—			(212	)
Dividends paid		(16	)		—			—			—			(16	)
Deferred financing fees		(2	)		—			—			—			(2	)
Cash provided by (used for) financing activities		105			(7	)		—			(328	)		(230	)
Effect of exchange rate changes on cash and cash equivalents		—			—			28			—			28
Increase in cash and cash equivalents		—			285			306			—			591
Cash and cash equivalents at beginning of the period		—			95			271			—			366
Cash and cash equivalents at end of the period	$	—		$	380		$	577		$	—		$	957

Recent Accounting Pronouncements (Policies)	9 Months Ended
Recent Accounting Pronouncements (Policies)	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Recent Accounting Pronouncements	Accounting Guidance Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” The objective of this standard is to remove inconsistent practices with regard to revenue recognition between U.S. GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with Topic 606. The provisions of ASU No. 2014-09 and its related updates will be effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company will adopt the standard on January 1, 2018 under the modified retrospective transition method. The Company’s project plan includes a three-phase approach to implementing the standard update. Phase one, the assessment phase, was completed in the first quarter of 2017. In this initial phase, the Company (a) conducted internal surveys of its businesses, (b) held revenue recognition workshops with sales and business unit finance leadership and (c) reviewed a representative sample of revenue arrangements across all businesses to initially identify a set of applicable qualitative revenue recognition changes related to the standard. The Company has also completed phase two of the project, which included (a) establishing and documenting key accounting positions, (b) assessing new disclosure requirements, business process and control impacts and (c) beginning to determine the initial quantitative impacts resulting from the standard. Phase three will include (a) finalizing any changes to accounting policies, (b) preparing new disclosures, (c) implementing new business processes and controls as needed and (d) quantifying the effect of adoption on opening retained earnings. Based on the analysis conducted to date, the Company believes that the adoption of the standard will not have a material impact on its consolidated financial statements. Substantially all of the Company’s revenue consists of sales of products that represent a single performance obligation where control transfers at the point in time title and risk of loss pass to the customer. The Company continues to evaluate the impact of the standard update on its consolidated financial statements and related disclosures and additional differences may be identified as new or amended contracts with customers that will impact future periods are executed. The Company expects that disclosure in the notes to the consolidated financial statements related to revenue recognition will be expanded in line with the requirements of the standard to further describe the nature, timing and uncertainty of revenue and cash flows arising from contracts with customers. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents an improvement over previous U.S. GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early application of the amendments in this update is permitted for all entities. At adoption, the Company will recognize a right-of-use asset and a lease liability initially measured at the present value of its operating lease payments. The Company is currently evaluating the other impacts of adopting this guidance on its financial position, results of operations and cash flows. In August 2016, the FASB issued various updates to ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”, which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method (unless impractical to do so) for each period presented and earlier application is permitted. Chemours does not expect that the adoption will have a significant impact on its cash flows. In March 2017, the FASB issued ASU No. 2017-07, “Compensation - Retirement Benefits (Topic 715)”, which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The guidance is effective for public business entities for annual periods beginning after December 15, 2017, as well as interim periods within those annual periods. The amendments in this update should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. Early adoption is permitted within the first interim period of an annual period for which financial statements have not been issued or made available for issuance. Chemours does not expect that the adoption will have a significant impact on its financial position, results of operations or cash flows. In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging (Topic 815)”, which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The guidance is effective for public business entities for fiscal years beginning after December 15, 2018, as well as interim periods within those fiscal years. Early adoption is permitted in any interim period. The amendments in this update should be applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. Chemours is currently evaluating the impact of adopting this guidance on its financial position, results of operations and cash flows. Recently Adopted Accounting Guidance In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718).” The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Chemours adopted this guidance effective January 1, 2017, and the adoption did not have a significant impact on the Company’s financial position, results of operations or cash flows except for the impact of windfall income tax benefits on share-based payments and the classification of employee withholding tax payments on vested restricted stock units (RSUs) as a financing activity on the statements of cash flows. Specific to the impact of windfall tax benefits, the Company expects the guidance will cause volatility in its income tax rates going forward. As of the adoption date, there were no windfall tax benefits from prior periods recognized; therefore, prior period adjustments were not required under a modified retrospective basis. For the three and nine months ended September 30, 2017, Chemours recognized $5 and $18 of windfall tax benefits, respectively, primarily from significant options exercised and RSUs vested, which were included in the provision for income taxes in the consolidated statements of operations. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to determine the fair value of the individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Any impairment charges recognized would not exceed the total amount of goodwill allocated to the reporting unit. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company has adopted this guidance and will implement its provisions for interim and annual goodwill impairment tests performed prospectively. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations or cash flows. In May 2017, the FASB issued ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting”, which provides clarity and reduces both diversity in practice and the cost and complexity of applying the guidance in Topic 718 to a change in the terms or conditions of a share-based payment award. Pursuant to this update, modification accounting is required to be applied to changes in the terms and conditions of a share-based payment award unless all of the following criteria remain unchanged before and after the award is modified: (a) the fair value of the award; (b) the vesting conditions of the award; and (c) the classification of the award as an equity instrument or a liability instrument. The amendments in this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and are to be applied prospectively to an award modified on or after the adoption date. Early adoption, including adoption in any interim period, is permitted for public business entities in reporting periods for which financial statements have not yet been issued. The Company has adopted this guidance and will implement its provisions prospectively for changes in the terms and conditions of share-based payment awards. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations or cash flows.

Restructuring and Asset Related Charges, Net (Tables)

9 Months Ended

Sep. 30, 2017

Restructuring And Related Activities [Abstract]

Schedule of Restructuring Program

For the three and nine months ended September 30, 2017 and 2016, Chemours recorded restructuring and asset-related charges, net as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Restructuring-related charges:
Employee separation charges	$	—	$	1	$	5	$	3
Decommissioning and other charges, net		8		13		26		38
Subtotal		8		14		31		41
Asset-related charges - impairment ¹		—		46		—		104
Total restructuring and asset-related charges, net	$	8	$	60	$	31	$	145

¹	The three and nine months ended September 30, 2016 include an impairment charge of $46 related to the aniline facility in Pascagoula, Mississippi. The nine months ended September 30, 2016 includes an impairment charge of $58 related to the sale of the Sulfur business.

Schedule of Restructuring Charges

Charges related to the Company’s restructuring programs impacted segment earnings for the three and nine months ended September 30, 2017 and 2016 as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Plant and product line closures¹:
Titanium Technologies	$	—	$	5	$	4	$	24
Fluoroproducts		—		1		3		6
Chemical Solutions		5		7		16		6
Subtotal		5		13		23		36
2015 Global Restructuring:
Titanium Technologies		—		—		—		2
Fluoroproducts		—		1		—		3
Chemical Solutions		—		—		—		—
Subtotal		—		1		—		5
2017 Restructuring Program		3		—		8		—
Total restructuring charges, net	$	8	$	14	$	31	$	41

¹	Includes charges related to employee separation and decommissioning costs in connection with the restructuring activities.

The following table shows the change in the employee separation-related liability account associated with the Company’s restructuring programs:

	Titanium Technologies Site Closures			Fluoro- Products Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			2017 Restructuring Program		Total
Balance at December 31, 2016	$	4		$	1		$	8		$	21		$	—	$	34
Charges to income		—			—			—			—			5		5
Payments		(3	)		(1	)		(4	)		(19	)		—		(27	)
Net currency translation and other adjustments ¹		—			—			—			1			—		1
Balance at September 30, 2017	$	1		$	—		$	4		$	3		$	5	$	13

¹	Amounts include net currency translation adjustment of less than $1 for the periods presented and rounding differences.

Other Income, Net (Tables)

9 Months Ended

Sep. 30, 2017

Other Income And Expenses [Abstract]

Schedule of Other Income

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017		2016
Leasing, contract services and miscellaneous income	$	7		$	6		$	24	$	18
Royalty income¹		2			3			12		11
Gain on sale of assets and businesses ²		—			169			14		258
Exchange (losses) gains, net ³		(4	)		(17	)		3		(37	)
Total other income, net	$	5		$	161		$	53	$	250

¹	Royalty income is primarily from technology and trademark licensing.

³	Exchange (losses) gains, net includes gains and losses on foreign currency forward contracts.

Earnings Per Share of Common Stock (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Numerator:
Net income attributable to Chemours	$	207	$	204	$	518	$	237
Denominator:
Weighted-average number of common shares outstanding - basic		185,431,036		181,596,161		184,641,599		181,452,194
Dilutive effect of the Company’s employee compensation plans ¹		6,206,778		1,932,395		5,909,015		1,089,738
Weighted-average number of common shares outstanding - diluted ¹		191,637,814		183,528,556		190,550,614		182,541,932

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following average number of stock options were anti-dilutive and, therefore, were not included in the diluted earnings per share calculation:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Average number of stock options		954		7,224,473		57,429		7,760,665

Accounts and Notes Receivable - Trade, Net (Tables)

9 Months Ended

Sep. 30, 2017

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable


	September 30, 2017		December 31, 2016
Accounts receivable - trade, net ¹	$	872	$	742
VAT, GST and other taxes ²		49		46
Other receivables ³		21		19
Total accounts and notes receivable - trade, net	$	942	$	807

¹	Accounts receivable - trade, net includes trade notes receivable and is net of allowances of $5 at September 30, 2017 and December 31, 2016. Allowances are equal to the estimated uncollectible amounts.

²	Value Added Tax (VAT) and Goods and Services Tax (GST).

³	Other receivables consist of advances and other deposits.

Inventories (Tables)

9 Months Ended

Sep. 30, 2017

Inventory Net [Abstract]

Schedule of Inventories

	September 30, 2017			December 31, 2016
Finished products	$	592		$	532
Semi-finished products		176			150
Raw materials, stores and supplies		309			285
Subtotal		1,077			967
Adjustment of inventories to LIFO basis		(200	)		(200	)
Total inventories	$	877		$	767

Other Assets (Tables)

9 Months Ended

Sep. 30, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Assets

	September 30, 2017		December 31, 2016
Capitalized repair and maintenance costs	$	105	$	145
Pension assets ¹		225		159
Deferred income taxes		38		41
Asset held for sale		—		29
Miscellaneous ²		36		43
Total other assets	$	404	$	417

Pension assets represent the funded status of certain of the Company's long-term employee benefit plans.

Other Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2017

Payables And Accruals [Abstract]

Schedule of Other Accrued Liabilities

	September 30, 2017		December 31, 2016
Compensation and other employee-related costs	$	147	$	154
Employee separation costs ¹		13		31
Accrued litigation ²		13		344
Environmental remediation ²		86		71
Income taxes		55		39
Customer rebates		70		53
Deferred revenue ³		9		76
Accrued interest		73		21
Miscellaneous ⁴		80		83
Total other accrued liabilities	$	546	$	872

¹	Current portion of employee separation costs.

²	Current portions of accrued litigation and environmental remediation. Accrued litigation includes the PFOA MDL Settlement accrual of $335 at December 31, 2016, which was paid in full by September 30, 2017.

³	Deferred revenue at December 31, 2016 includes $58 in outstanding prepayments by DuPont for specified goods and services. There were no such prepayments at September 30, 2017.

⁴	Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations and other miscellaneous accrued expenses.

Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

	September 30, 2017		December 31, 2016
Senior secured term loans:
Tranche B term loan due May 2022	$	—	$	1,372
Tranche B-1 Dollar Term Loan due May 2022		925		—
Tranche B-1 Euro Term Loan due May 2022 (€395 at September 30, 2017 and €0 at December 31, 2016)		464		—
Senior unsecured notes:
6.625% due May 2023		1,158		1,158
7.000% due May 2025		750		750
6.125% due May 2023 (€295 at September 30, 2017 and December 31, 2016)		346		308
5.375% due May 2027		500		—
Capital lease obligations		3		3
Total debt		4,146		3,591
Less: Unamortized issue discounts		9		5
Less: Unamortized debt issuance costs		42		42
Less: Current maturities of long-term debt		14		15
Total long-term debt, net	$	4,081	$	3,529

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2017

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy:

		Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2017		December 31, 2016
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	3	$	2
Total asset derivatives		$	3	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	4
Total liability derivatives		$	4	$	4

Schedule of Derivative Liabilities at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy:

		Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2017		December 31, 2016
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	3	$	2
Total asset derivatives		$	3	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	4
Total liability derivatives		$	4	$	4

Long-term Employee Benefits (Tables)

9 Months Ended

Sep. 30, 2017

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Schedules of Net Periodic Pension Income

The components of net periodic pension income for all significant pension plans were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net periodic pension cost (income):
Service cost	$	4		$	3		$	11		$	10
Interest cost		4			5			11			15
Expected return on plan assets		(18	)		(16	)		(52	)		(49	)
Amortization of actuarial loss		5			9			15			20
Amortization of prior service gain		(1	)		—			(1	)		(1	)
Curtailment gain		—			—			—			(2	)
Settlement loss		1			—			1			—
Net periodic pension (income) cost	$	(5	)	$	1		$	(15	)	$	(7	)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Options Weighted Average Assumptions

The expense related to stock options granted in the nine months ended September 30, 2017 was based on the weighted-average assumptions shown in the table below:

	Nine Months Ended September 30, 2017
Risk-free interest rate		2.14	%
Expected term (years)		6.00
Volatility		44.49	%
Dividend yield		0.35	%
Fair value per stock option	$	15.21

Schedule of Stock Options Activity

The following table summarizes Chemours’ stock option activity for the nine months ended September 30, 2017:

	Number of Shares (in thousands)			Weighted-Average Exercise Price (per share)		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Granted		878			34.84
Exercised		(1,987	)		14.41
Forfeited		(40	)		19.10
Expired		(28	)		12.00
Outstanding, September 30, 2017		6,792		$	15.69		5.27	$	237,179
Exercisable, September 30, 2017		3,814		$	14.03		3.63	$	139,523

Schedule of Restricted Stock Units Activity

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		2,316		$	11.23
Granted		211			36.42
Vested		(1,275	)		11.09
Forfeited		(39	)		15.10
Non-vested, September 30, 2017		1,213		$	15.46

Schedule of Performance Share Units Activity

The following table provides compensation costs for stock-based compensation related to PSUs at 100% of target amounts:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		803		$	6.10
Granted		211			40.30
Vested		—			—
Forfeited		(27	)		16.62
Non-vested, September 30, 2017		987		$	12.94

Segment Information (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Schedule of Segment Information

Three Months Ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	799	$	637	$	148	$	—		$	1,584
Adjusted EBITDA		249		158		18		(44	)		381
Depreciation and amortization		24		28		4		6			62

2016
Net sales to external customers	$	625	$	591	$	182	$	—		$	1,398
Adjusted EBITDA		144		143		9		(28	)		268
Depreciation and amortization		32		26		6		9			73

Nine Months Ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	2,173	$	1,998	$	437	$	—		$	4,608
Adjusted EBITDA		601		510		37		(120	)		1,028
Depreciation and amortization		89		81		13		21			204

2016
Net sales to external customers	$	1,742	$	1,695	$	641	$	—		$	4,078
Adjusted EBITDA		309		333		30		(89	)		583
Depreciation and amortization		87		75		24		26			212

Reconciliation of EBITDA from Segments to Consolidated

The following is a tabular reconciliation of consolidated income before income taxes to Adjusted EBITDA:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Income before income taxes	$	250		$	234		$	649		$	262
Interest expense, net		55			51			161			157
Depreciation and amortization		62			73			204			212
Non-operating pension and other post-retirement employee benefit income		(7	)		(5	)		(24	)		(19	)
Exchange losses (gains)		4			17			(3	)		37
Restructuring charges		8			14			31			41
Asset-related charges		1			46			3			109
Gain on sale of assets and businesses		—			(169	)		(14	)		(258	)
Transaction costs ¹		1			2			3			18
Legal and other charges ²		7			5			18			24
Adjusted EBITDA	$	381		$	268		$	1,028		$	583

¹	Includes accounting, legal and bankers’ transaction fees incurred related to the Company's strategic initiatives.

²	Includes litigation settlements, water treatment accruals related to PFOA, employee separation costs and lease termination charges.

Guarantor Condensed Consolidating Financial Information (Tables)

9 Months Ended

Sep. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidating Statements of Comprehensive Income

	Three Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	960	$	1,053		$	(429	)	$	1,584
Cost of goods sold		—			773		753			(409	)		1,117
Gross profit		—			187		300			(20	)		467
Selling, general and administrative expense		7			105		43			(7	)		148
Research and development expense		—			19		1			—			20
Restructuring and asset-related charges, net		—			8		—			—			8
Total expenses		7			132		44			(7	)		176
Equity in earnings of affiliates		—			—		9			—			9
Equity in earnings of subsidiaries		233			—		—			(233	)		—
Interest (expense) income, net		(57	)		2		—			—			(55	)
Intercompany interest income (expense), net		16			—		(16	)		—			—
Other income (expense), net		6			22		(17	)		(6	)		5
Income before income taxes		191			79		232			(252	)		250
(Benefit from) provision for income taxes		(16	)		18		42			(1	)		43
Net income		207			61		190			(251	)		207
Less: Net income attributable to non-controlling interests		—			—		—			—			—
Net income attributable to Chemours	$	207		$	61	$	190		$	(251	)	$	207
Comprehensive income attributable to Chemours	$	228		$	63	$	225		$	(288	)	$	228

	Three Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	961		$	847		$	(410	)	$	1,398
Cost of goods sold		—			791			656			(391	)		1,056
Gross profit		—			170			191			(19	)		342
Selling, general and administrative expense		5			115			34			(6	)		148
Research and development expense		—			19			—			—			19
Restructuring and asset-related charges, net		—			60			—			—			60
Total expenses		5			194			34			(6	)		227
Equity in earnings of affiliates		—			1			8			—			9
Equity in earnings of subsidiaries		226			—			—			(226	)		—
Interest expense, net		(50	)		(1	)		—			—			(51	)
Intercompany interest income (expense), net		15			1			(16	)		—			—
Other income, net		5			70			94			(8	)		161
Income before income taxes		191			47			243			(247	)		234
(Benefit from) provision for income taxes		(13	)		29			29			(15	)		30
Net income		204			18			214			(232	)		204
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income attributable to Chemours	$	204		$	18		$	214		$	(232	)	$	204
Comprehensive income attributable to Chemours	$	210		$	18		$	226		$	(244	)	$	210

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,904	$	2,941		$	(1,237	)	$	4,608
Cost of goods sold		—			2,358		2,210			(1,227	)		3,341
Gross profit		—			546		731			(10	)		1,267
Selling, general and administrative expense		26			339		101			(22	)		444
Research and development expense		—			57		4			—			61
Restructuring and asset-related charges, net		—			28		3			—			31
Total expenses		26			424		108			(22	)		536
Equity in earnings of affiliates		—			—		26			—			26
Equity in earnings of subsidiaries		594			—		—			(594	)		—
Interest (expense) income, net		(164	)		1		2			—			(161	)
Intercompany interest income (expense), net		48			—		(48	)		—			—
Other income (expense), net		19			93		(37	)		(22	)		53
Income before income taxes		471			216		566			(604	)		649
(Benefit from) provision for income taxes		(47	)		40		136			1			130
Net income		518			176		430			(605	)		519
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	518		$	176	$	429		$	(605	)	$	518
Comprehensive income attributable to Chemours	$	675		$	178	$	640		$	(818	)	$	675

	Nine Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,898		$	2,367		$	(1,187	)	$	4,078
Cost of goods sold		—			2,506			1,921			(1,160	)		3,267
Gross profit		—			392			446			(27	)		811
Selling, general and administrative expense		17			350			103			(16	)		454
Research and development expense		—			58			2			—			60
Restructuring and asset-related charges (credits), net		—			147			(2	)		—			145
Total expenses		17			555			103			(16	)		659
Equity in (loss) earnings of affiliates		—			(2	)		19			—			17
Equity in earnings of subsidiaries		307			—			—			(307	)		—
Interest expense, net		(155	)		(2	)		—			—			(157	)
Intercompany interest income (expense), net		44			4			(48	)		—			—
Other income, net		15			178			72			(15	)		250
Income before income taxes		194			15			386			(333	)		262
(Benefit from) provision for income taxes		(43	)		25			53			(10	)		25
Net income (loss)		237			(10	)		333			(323	)		237
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	237		$	(10	)	$	333		$	(323	)	$	237
Comprehensive income (loss) attributable to Chemours	$	250		$	(10	)	$	355		$	(345	)	$	250

Condensed Consolidating Balance Sheets

	September 30, 2017
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	504		$	1,031		$	—		$	1,535
Accounts and notes receivable - trade, net		—		316			626			—			942
Intercompany receivable		19		684			196			(899	)		—
Inventories		—		348			592			(63	)		877
Prepaid expenses and other		—		59			20			—			79
Deferred income taxes		—		—			—			—			—
Total current assets		19		1,911			2,465			(962	)		3,433
Property, plant and equipment		—		6,346			2,066			—			8,412
Less: Accumulated depreciation		—		(4,410	)		(1,052	)		—			(5,462	)
Property, plant and equipment, net		—		1,936			1,014			—			2,950
Goodwill and other intangible assets, net		—		153			14			—			167
Investments in affiliates		—		—			166			—			166
Investment in subsidiaries		4,114		—			—			(4,114	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		35		101			292			(24	)		404
Total assets	$	5,318	$	4,101		$	3,951		$	(6,250	)	$	7,120
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	589		$	421		$	—		$	1,010
Current maturities of long-term debt		14		—			—			—			14
Intercompany payable		354		196			349			(899	)		—
Other accrued liabilities		72		310			164			—			546
Total current liabilities		440		1,095			934			(899	)		1,570
Long-term debt, net		4,078		3			—			—			4,081
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		107			92			(24	)		175
Other liabilities		—		392			97			—			489
Total liabilities		4,518		1,597			2,273			(2,073	)		6,315
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		800		2,504			1,673			(4,177	)		800
Non-controlling interests		—		—			5			—			5
Total equity		800		2,504			1,678			(4,177	)		805
Total liabilities and equity	$	5,318	$	4,101		$	3,951		$	(6,250	)	$	7,120

Condensed Consolidating Balance Sheets

	December 31, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	224		$	678		$	—		$	902
Accounts and notes receivable - trade, net		—		299			508			—			807
Intercompany receivable		3		1,050			46			(1,099	)		—
Inventories		—		341			476			(50	)		767
Prepaid expenses and other		—		38			32			7			77
Total current assets		3		1,952			1,740			(1,142	)		2,553
Property, plant and equipment, net		—		6,136			1,861			—			7,997
Less: Accumulated depreciation		—		(4,285	)		(928	)		—			(5,213	)
Property, plant and equipment, net		—		1,851			933			—			2,784
Goodwill and other intangible assets, net		—		156			14			—			170
Investments in affiliates		—		—			136			—			136
Investment in subsidiaries		3,258		—			—			(3,258	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		13		178			226			—			417
Total assets	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	573		$	311		$	—		$	884
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		762		46			291			(1,099	)		—
Other accrued liabilities		21		718			133			—			872
Total current liabilities		798		1,337			735			(1,099	)		1,771
Long-term debt, net		3,526		3			—			—			3,529
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		59			73			—			132
Other liabilities		—		428			96			—			524
Total liabilities		4,324		1,827			2,054			(2,249	)		5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		100		2,310			991			(3,301	)		100
Non-controlling interests		—		—			4			—			4
Total equity		100		2,310			995			(3,301	)		104
Total liabilities and equity	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060

Condensed Consolidating Statements of Cash Flows

	Nine Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(60	)	$	32		$	364		$	—		$	336
Investing activities
Purchases of property, plant and equipment		—			(204	)		(42	)		—			(246	)
Proceeds from sales of assets and businesses, net		—			39			—			—			39
Intercompany investing activities		—			408			—			(408	)		—
Foreign exchange contract settlements, net		—			5			—			—			5
Cash provided by (used for) investing activities		—			248			(42	)		(408	)		(202	)
Financing activities
Proceeds from the issuance of debt, net		494			—			—			—			494
Intercompany short-term borrowing repayments, net		(408	)		—			—			408			—
Debt repayments		(24	)		—			—			—			(24	)
Dividends paid		(16	)		—			—			—			(16	)
Debt issuance costs		(6	)		—			—			—			(6	)
Tax payments related to withholdings on vested restricted stock units		(10	)		—			—			—			(10	)
Proceeds from issuance of stock options, net		30			—			—			—			30
Cash provided by financing activities		60			—			—			408			468
Effect of exchange rate changes on cash and cash equivalents		—			—			31			—			31
Increase in cash and cash equivalents		—			280			353			—			633
Cash and cash equivalents at beginning of the period		—			224			678			—			902
Cash and cash equivalents at end of the period	$	—		$	504		$	1,031		$	—		$	1,535

Condensed Consolidating Statements of Cash Flows

	Nine Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(105	)	$	173		$	256		$	—		$	324
Investing activities
Purchases of property, plant and equipment		—			(142	)		(93	)		—			(235	)
Proceeds from sales of assets and businesses, net		—			590			117			—			707
Intercompany investing activities		—			(328	)		—			328			—
Foreign exchange contract settlements		—			(1	)		—			—			(1	)
Investment in affiliates		—			—			(2	)		—			(2	)
Cash provided by investing activities		—			119			22			328			469
Financing activities
Intercompany short-term borrowings, net		328			—			—			(328	)		—
Debt repayments		(205	)		(7	)		—			—			(212	)
Dividends paid		(16	)		—			—			—			(16	)
Deferred financing fees		(2	)		—			—			—			(2	)
Cash provided by (used for) financing activities		105			(7	)		—			(328	)		(230	)
Effect of exchange rate changes on cash and cash equivalents		—			—			28			—			28
Increase in cash and cash equivalents		—			285			306			—			591
Cash and cash equivalents at beginning of the period		—			95			271			—			366
Cash and cash equivalents at end of the period	$	—		$	380		$	577		$	—		$	957

Recent Accounting Pronouncements (Narrative) (Details) - ASU 2016-09 [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
New Accounting Pronouncement Early Adoption [Line Items]
Tax benefits from significant options exercised and RSUs vested	$ 5	$ 18
Stock Options Exercised and RSUs Vested [Member]
New Accounting Pronouncement Early Adoption [Line Items]
Tax benefits from significant options exercised and RSUs vested	$ 5	$ 18

Restructuring and Asset Related Charges, Net (Charges) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Employee separation charges	$ 0	$ 1	$ 5	$ 3
Decommissioning and other charges, net	8	13	26	38
Subtotal	8	14	31	41
Asset-related charges - impairment	0	46	0	104
Total restructuring and asset-related charges, net	$ 8	60	$ 31	145
Disposed by Sale [Member] \| Sulfur Business [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment				58
Pascagoula, Mississippi [Member] \| Aniline Facility [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment		$ 46		$ 46

Restructuring and Asset Related Charges, Net (Segment Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	$ 8	$ 14	$ 31	$ 41
2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	1	0	5
2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	3	0	8	0
Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	5	13	23	36
Operating Segments [Member] \| Titanium Technologies [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	0	0	2
Operating Segments [Member] \| Titanium Technologies [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	5	4	24
Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net		1	3	6
Operating Segments [Member] \| Fluoroproducts [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	1	0	3
Operating Segments [Member] \| Fluoroproducts [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	1	3	6
Operating Segments [Member] \| Chemical Solutions [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	0	0	0
Operating Segments [Member] \| Chemical Solutions [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	$ 5	$ 7	$ 16	$ 6

Restructuring and Asset Related Charges, Net (Narrative) (Details)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 31, 2017 Employee	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2018 USD ($)
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges		$ 8,000,000		$ 14,000,000	$ 31,000,000	$ 41,000,000
2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges		3,000,000		0	8,000,000	0
2017 Restructuring Program [Member] \| Minimum [Member] \| Restructuring-Related Charges Expected to be Incurred Though December 31, 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							$ 45,000,000
2017 Restructuring Program [Member] \| Maximum [Member] \| Restructuring-Related Charges Expected to be Incurred Though December 31, 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							$ 55,000,000
Voluntary Separation Program [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Amounts recognized in consolidated financial statements					0
Voluntary Separation Program [Member] \| 2017 Restructuring Program [Member] \| Minimum [Member] \| Subsequent Event [Member]
Restructuring Cost and Reserve [Line Items]
Number of employees to be separated by end of 2018 \| Employee	300
Voluntary Separation Program [Member] \| 2017 Restructuring Program [Member] \| Maximum [Member] \| Subsequent Event [Member]
Restructuring Cost and Reserve [Line Items]
Number of employees to be separated by end of 2018 \| Employee	350
Titanium Technologies [Member] \| Operating Segments [Member] \| Edge Moor Plant [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs, excluding non-cash asset-related charges			$ 60,000,000
Titanium Technologies [Member] \| Operating Segments [Member] \| Decommissioning and Dismantling Costs [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges				5,000,000	4,000,000	24,000,000
Fluoroproducts [Member] \| Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges				1,000,000	3,000,000	6,000,000
Restructuring costs, excluding non-cash asset-related charges					17,000,000
Chemical Solutions [Member] \| Operating Segments [Member] \| Niagara Falls, NY [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs, excluding non-cash asset-related charges					30,000,000
Chemical Solutions [Member] \| Operating Segments [Member] \| Decommissioning and Dismantling Costs [Member] \| Niagara Falls, NY [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges		5,000,000		$ 7,000,000	16,000,000	$ 6,000,000
Chemical Solutions [Member] \| Operating Segments [Member] \| Decommissioning and Site Redevelopment [Member] \| Niagara Falls, NY [Member]
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges expected to be incurred in 2017		$ 5,000,000			$ 5,000,000

Restructuring and Asset Related Charges, Net (Restructuring Program Schedule) (Details)	9 Months Ended
	Sep. 30, 2017 USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	$ 34,000,000
Charges to income	5,000,000
Payments	(27,000,000)
Net currency translation and other adjustment	1,000,000
Restructuring reserve, ending	13,000,000
Maximum [Member]
Restructuring Reserve [Roll Forward]
Net currency translation and other adjustment	1,000,000
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	4,000,000
Charges to income	0
Payments	(3,000,000)
Net currency translation and other adjustment	0
Restructuring reserve, ending	1,000,000
Fluoro-Products Lines Shutdown [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	1,000,000
Charges to income	0
Payments	(1,000,000)
Net currency translation and other adjustment	0
Restructuring reserve, ending	0
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	8,000,000
Charges to income	0
Payments	(4,000,000)
Net currency translation and other adjustment	0
Restructuring reserve, ending	4,000,000
2015 Global Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	21,000,000
Charges to income	0
Payments	(19,000,000)
Net currency translation and other adjustment	1,000,000
Restructuring reserve, ending	3,000,000
2017 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0
Charges to income	5,000,000
Payments	0
Net currency translation and other adjustment	0
Restructuring reserve, ending	$ 5,000,000

Other Income,Net (Schedule of Other Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Other Income And Expenses [Abstract]
Leasing, contract services and miscellaneous income	$ 7	$ 6	$ 24	$ 18
Royalty income	2	3	12	11
Gain on sale of assets and businesses	0	169	14	258
Exchange (losses) gains, net	(4)	(17)	3	(37)
Total other income, net	$ 5	$ 161	$ 53	$ 250

Other Income,Net (Schedule of Other Income) (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Edge Moor Site [Member]
Component of Other Income [Line Items]
Gain on sale of asset		$ 12
Clean and Disinfect Product Line [Member]
Component of Other Income [Line Items]
Gain on sale of asset	$ 169
Beaumont Site [Member]
Component of Other Income [Line Items]
Gain on sale of asset			$ 89

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Tax Credit Carryforward [Line Items]
Provision for income taxes	$ 43	$ 30	$ 130	$ 25
Effective income tax rate	17.00%	13.00%	20.00%	10.00%
U.S Federal [Member]
Tax Credit Carryforward [Line Items]
Valuation allowance	$ 65		$ 65		$ 50
ASU 2016-09 [Member]
Tax Credit Carryforward [Line Items]
Income tax benefit from windfalls on share-based payments	$ 5		$ 18

Earnings Per Share of Common Stock (Earnings per Share Calculation) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net income attributable to Chemours	$ 207	$ 204	$ 518	$ 237
Denominator:
Weighted-average number of common shares outstanding - basic	185,431,036	181,596,161	184,641,599	181,452,194
Dilutive effect of the Company’s employee compensation plans	6,206,778	1,932,395	5,909,015	1,089,738
Weighted average number of common shares outstanding - diluted	191,637,814	183,528,556	190,550,614	182,541,932

Earnings Per Share of Common Stock (Anti-dilutive Shares Excluded from Computation of Earnings per Share) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Average number of stock options	954	7,224,473	57,429	7,760,665

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Receivables [Abstract]
Accounts receivable - trade, net	$ 872	$ 742
VAT, GST and other taxes	49	46
Other receivables	21	19
Total accounts and notes receivable - trade, net	$ 942	$ 807

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Parenthetical) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Receivables [Abstract]
Allowance for doubtful accounts receivable	$ 5	$ 5

Accounts and Notes Receivable - Trade, Net (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Accounts Notes And Loans Receivable [Line Items]
Bad debt expense		$ 7,000,000		$ 7,000,000
Maximum [Member]
Accounts Notes And Loans Receivable [Line Items]
Bad debt expense	$ 1,000,000		$ 1,000,000

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Inventory Net [Abstract]
Finished products	$ 592	$ 532
Semi-finished products	176	150
Raw materials, stores and supplies	309	285
Subtotal	1,077	967
Adjustment of inventories to LIFO basis	(200)	(200)
Total inventories	877	767
LIFO inventory amount	$ 472	$ 465
Percentage of LIFO inventory	44.00%	48.00%

Property, Plant and Equipment, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 61	$ 72	$ 201	$ 210
Capital leased assets	$ 5		$ 5		$ 5

Other Assets (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Other Assets [Line Items]
Capitalized repair and maintenance costs	$ 105	$ 145
Pension assets	225	159
Deferred income taxes	38	41
Asset held for sale		29
Miscellaneous	36	43
Total other assets	404	417
Life insurance policies cash surrender value	63	61
Outstanding loans from policy issuer	63	61
Revolving Credit Facility [Member]
Other Assets [Line Items]
Deferred financing fee	$ 10	$ 13

Other Assets (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
Other Assets (Narrative) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Sep. 30, 2017
Other Assets [Line Items]
Other assets, impairment charges		$ 13
Net proceeds from sale and leaseback transaction	$ 29
Sale and leaseback transaction, deferred gain	2
Senior secured term loan [Member]
Other Assets [Line Items]
Repayment of senior secured term loans	$ 13

Other Accrued Liabilities (Details) - USD ($)

9 Months Ended

May 23, 2017

Sep. 30, 2017

Dec. 31, 2016

Accrued Liabilities, Current [Abstract]

Compensation and other employee-related costs

$ 147,000,000

$ 154,000,000

Employee separation costs

^[1]

13,000,000

31,000,000

Accrued litigation

^[2]

13,000,000

344,000,000

Environmental remediation

^[2]

86,000,000

71,000,000

Income taxes

55,000,000

39,000,000

Customer rebates

70,000,000

53,000,000

Deferred revenue

^[3]

9,000,000

76,000,000

Accrued interest

73,000,000

21,000,000

Miscellaneous

^[4]

80,000,000

83,000,000

Total other accrued liabilities

546,000,000

872,000,000

Outstanding prepayments by DuPont for specified goods and services

58,000,000

PFOA MDL Settlement [Member]

Accrued Liabilities, Current [Abstract]

Accrued litigation

$ 335,000,000

Settlement payments

$ 335,000,000

[1]	Current portion of employee separation costs.
[2]	Current portions of accrued litigation and environmental remediation. Accrued litigation includes the PFOA MDL Settlement accrual of $335 at December 31, 2016, which was paid in full by September 30, 2017.
[3]	Deferred revenue at December 31, 2016 includes $58 in outstanding prepayments by DuPont for specified goods and services. There were no such prepayments at September 30, 2017.
[4]	Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations and other miscellaneous accrued expenses.

Debt (Components of Long-Term Debt) (Details) € in Millions, $ in Millions	Sep. 30, 2017 USD ($)	Sep. 30, 2017 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)
Debt Instrument [Line Items]
Capital lease obligations	$ 3		$ 3
Total debt	4,146		3,591
Less: Unamortized issue discounts	9		5
Less: Unamortized debt issuance costs	42		42
Current maturities of long-term debt	14		15
Total long-term debt, net	4,081		3,529
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,158		$ 1,158
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%
Senior unsecured notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 346		$ 308
Long-term debt, gross \| €		€ 295		€ 295
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%
Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 500
Debt instrument interest rate	5.375%	5.375%	5.375%	5.375%
Senior Secured Tranche B Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt			$ 1,372
Senior Secured Tranche B-1 Dollar Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 925
Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 464
Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross \| €		€ 395		€ 0

Debt (Senior Secured Credit Facilities) (Details)		3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended	17 Months Ended
Debt (Senior Secured Credit Facilities) (Details)	Apr. 03, 2017 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2017	Sep. 30, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 01, 2019	Apr. 03, 2017 EUR (€)
Line of Credit Facility [Line Items]
Loss on debt extinguishment and related fees		$ 3,000,000
Senior secured term loan [Member]
Line of Credit Facility [Line Items]
Debt instrument term				7 years
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term				5 years
Line of credit facility, maximum borrowing capacity				$ 750,000,000
Long-term debt				0	$ 0
Letters of credit outstanding				$ 102,000,000	$ 132,000,000
Commitment fee percentage				0.20%
Maximum net leverage ratio			3.00%		3.50%
Minimum interest coverage ratio			1.75%
Revolving Credit Facility [Member] \| Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio						2.00%
Maximum net leverage ratio decrease, semi-annually						0.25%
Minimum interest coverage ratio						3.00%
Minimum coverage ratio increase, semi-annually						0.25%
Revolving Credit Facility [Member] \| Base Rate
Line of Credit Facility [Line Items]
Variable rate				0.50%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate				1.50%
Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage				0.20%
Revolving Credit Facility [Member] \| Minimum [Member] \| Base Rate
Line of Credit Facility [Line Items]
Variable rate				0.50%
Revolving Credit Facility [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate				1.50%
Revolving Credit Facility [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage				0.35%
Revolving Credit Facility [Member] \| Maximum [Member] \| Base Rate
Line of Credit Facility [Line Items]
Variable rate				1.25%
Revolving Credit Facility [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate				2.25%
Euro Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity \| €							€ 400,000,000
Line of credit facility, maturity date	May 12, 2022
Effective interest rates on senior secured term loan				3.00%
Euro Term Loan [Member] \| Minimum [Member] \| Euro Interbank Offered Rate (EURIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	0.75%
Euro Term Loan [Member] \| Maximum [Member] \| Euro Interbank Offered Rate (EURIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	2.25%
Dollar Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 940,000,000
Line of credit facility, maturity date	May 12, 2022
Effective interest rates on senior secured term loan				3.74%
Dollar Term Loan [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	0.00%
Dollar Term Loan [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	2.50%

Debt (Senior Unsecured Notes) (Details) - USD ($) $ in Millions		9 Months Ended
	May 23, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Proceeds from issuance of debt, net		$ 494	$ 0
Debt instrument net issue discount		9		$ 5
Senior unsecured notes [Member]
Debt Instrument [Line Items]
Proceeds from issuance of debt, net	$ 489
Senior unsecured notes [Member] \| 2027 Notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 500
Debt instrument interest rate	5.375%
Debt instrument net issue discount	$ 5
Underwriting fees and other related expenses	6
Obligation threshold for debt to become guaranteed	$ 100
Repurchase price obligation, percentage of principal amount redeemed in event of change of contract	101.00%
Repurchase price obligation, percentage of principal amount redeemed	100.00%
PFOA MDL Settlement [Member]
Debt Instrument [Line Items]
Settlement payments	$ 335	$ 335

Debt (Maturities and Fair Value) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2022 and beyond	$ 4,085
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%	6.625%
Senior unsecured notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%	7.00%
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%
Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.375%	5.375%
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 1,235
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	834
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	372
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 520
Senior secured term loan [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2017	$ 3
2018	14
2019	14
2020	14
2021	$ 14
Additional principal repayment, percentage of excess cash flow		50.00%
Additional principal repayment, percentage of excess cash flow, stepdown level one		25.00%
Additional principal repayment, percentage of excess cash flow, stepdown level two		0.00%
Target leverage ratio		3.00%
Principal repayment, percentage of excess cash flow	0.00%
Euro Term Loan [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 469
The Dollar Term Loans[Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 931

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details)			1 Months Ended	3 Months Ended				9 Months Ended	12 Months Ended
	May 23, 2017 USD ($)	Oct. 20, 2015 USD ($)	May 31, 2013 doctor water_district	Sep. 30, 2017 USD ($) lawsuit	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) lawsuit plaintiff subpoena	Dec. 31, 2016 USD ($) lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Jan. 31, 2012 USD ($)
Fayetteville North Carolina
Loss Contingencies [Line Items]
Number of federal grand jury subpoenas \| subpoena								2
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				$ 510,000,000				$ 510,000,000
PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Settlement payments	$ 335,000,000							335,000,000
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements								1,000,000
MDL Settlement [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 335,000,000				335,000,000	$ 335,000,000
Settlement payments								$ 335,000,000
Date of Agreement								Mar. 31, 2017
Total settlement amount						$ 670,700,000
Post-MDL Settlement Injury Matters [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				3				3
Number of plaintiffs declined \| plaintiff								10
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit				20				20	27
Years of exposure to benzene		24 years
Compensatory damages awarded		$ 6,900,000
Punitive damages awarded		$ 1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 15,000,000				$ 15,000,000	$ 349,000,000
Additional estimated charges							$ 4,000,000
PFOA Matters [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments								$ 25,000,000
Period of payments								5 years
PFOA Matters [Member] \| PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Additional estimated charges									$ 335,000,000
Settlement payments				320,000,000	$ 15,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident											80,000
Number of doctors to release initial screening recommendations \| doctor			3
Number of water districts Company must provide treatment \| water_district			6
PFOA Matters: Drinking Water Actions [Member] \| Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments										$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] \| Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments										$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				$ 235,000,000				$ 235,000,000
Escrow deposit												$ 1,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				3,500				3,500
DuPont [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments								$ 25,000,000
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				1,600				1,600	1,900
Accrual balance				$ 41,000,000				$ 41,000,000	$ 41,000,000

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 268		$ 278
Environmental remediation expense	$ 36	$ 16
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	20 years
Loss contingency, potential additional loss	$ 510

Financial Instruments (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended
Financial Instruments (Narrative) (Details) $ in Millions	Sep. 30, 2017 USD ($) contract	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) contract	Sep. 30, 2016 USD ($)
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Recognized loss on derivative net investment hedge, pre-tax	$ (26)	$ (6)	$ (76)	$ (9)
Foreign currency forward contracts [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	26		26
Derivative notional value	$ 619		$ 619
Foreign currency forward contracts [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income (Expense), Net [Member]
Derivative [Line Items]
Derivative gain (loss)	$ (1)	$ (2)	$ 6	$ (2)

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Fair Value, Measurements, Recurring [Member] - Fair Value, Inputs, Level 2 [Member] - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 3	$ 2
Liability derivatives	4	4
Foreign currency forward contracts [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	3	2
Foreign currency forward contracts [Member] \| Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 4	$ 4

Long-term Employee Benefits (Schedules of Net Periodic Pension Income) (Details) - Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net periodic pension cost (income):
Service cost	$ 4	$ 3	$ 11	$ 10
Interest cost	4	5	11	15
Expected return on plan assets	(18)	(16)	(52)	(49)
Amortization of actuarial loss	5	9	15	20
Amortization of prior service gain	(1)		(1)	(1)
Curtailment gain				(2)
Settlement loss	1		1
Net periodic pension (income) cost	$ (5)	$ 1	$ (15)	$ (7)

Long-term Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2017
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer		$ 4	$ 14
Estimated future employer contributions in current fiscal year		$ 11	11
U.S. Pension Restoration Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer			$ 10
Subsequent Event [Member] \| U.S. Pension Restoration Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment to settle remaining liability	$ 10

Stock-based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions		3 Months Ended		9 Months Ended
	Jan. 26, 2017 Period shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Apr. 26, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost \| $		$ 6	$ 6	$ 21	$ 17
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares reserved for issuance	7,000,000
Consecutive offering periods	12 months
Number of purchase periods in offer period \| Period	4
Employee stock purchase plan initial offering period	Oct. 02, 2017
Percentage of common stock discount rate equal to the fair value	95.00%
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				10 years
Stock-based compensation award vesting period				3 years
Total intrinsic value of options exercised \| $				$ 42
Unrecognized compensation cost related to stock options \| $		$ 8		$ 8
Unrecognized compensation cost period for recognition				2 years 2 months 5 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period				3 years
Unrecognized compensation cost period for recognition				9 months 11 days
Shares issued upon conversion of equity award		1		1
Unrecognized compensation cost related to equity awards other than options \| $		$ 7		$ 7
Weighted-average fair value at grant date (in dollars per share) \| $ / shares				$ 36.42
Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost \| $		$ 2	$ 1	$ 5	$ 1
Stock-based compensation award vesting period				3 years
Shares issued upon conversion of equity award		1		1
Percentage of target award available for grant				100.00%
Weighted-average fair value at grant date (in dollars per share) \| $ / shares		$ 55.02		$ 40.30
Number of additional shares to be awarded				450,000
Performance Share Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant				0.00%
Performance Share Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant				200.00%
Chemours Company Equity and Incentive Plan (the “Prior Plan”) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants (in shares)		13,500,000		13,500,000		0
Shares issued upon conversion of equity stock option awards granted						1
Shares issued upon conversion of equity stock other than option awards granted						1.5
Chemours Company 2017 Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants (in shares)		17,650,034		17,650,034
Shares authorized for grants (in shares)						19,000,000
ASU 2016-09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit from windfalls on share-based payments \| $		$ 5		$ 18

Stock-based Compensation (Stock Option Weighted Average Assumptions) (Details) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2017 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.14%
Expected term (years)	6 years
Volatility	44.49%
Dividend yield	0.35%
Fair value per stock option	$ 15.21

Stock-based Compensation (Stock Option Activity) (Details) - Stock Option [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance, shares	7,969
Granted, shares	878
Exercised, shares	(1,987)
Forfeited, shares	(40)
Expired, shares	(28)
Outstanding, ending balance, shares	6,792	7,969
Exercisable, shares	3,814
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 13.72
Granted, weighted average exercise price (in dollars per share)	34.84
Exercised, weighted average exercise price (in dollars per share)	14.41
Forfeited, weighted average exercise price (in dollars per share)	19.10
Expired, weighted average exercise price (in dollars per share)	12.00
Outstanding, weighted average exercise price, ending balance (in dollars per share)	15.69	$ 13.72
Exercisable, weighted average exercise price (in dollars per share)	$ 14.03
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	5 years 3 months 7 days	5 years 29 days
Options exercisable, weighted average remaining contractual term	3 years 7 months 17 days
Options outstanding, aggregate intrinsic value	$ 66,668
Options outstanding, aggregate intrinsic value	237,179	$ 66,668
Options exercisable, aggregate intrinsic value	$ 139,523

Stock-based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested, beginning balance, shares \| shares	2,316
Granted, shares \| shares	211
Vested, shares \| shares	(1,275)
Forfeited, shares \| shares	(39)
Non-vested, ending balance, shares \| shares	1,213
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 11.23
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	36.42
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	11.09
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	15.10
Non-vested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 15.46

Stock-based Compensation (Performance Share Units Activity) (Details) - Performance Share Units [Member] - $ / shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested, beginning balance, shares		803
Granted, shares		211
Vested, shares		0
Forfeited, shares		(27)
Non-vested, ending balance, shares	987	987
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, weighted average grant date fair value, beginning balance (in dollars per share)		$ 6.10
Granted, weighted average grant date fair value (in dollars per share)	$ 55.02	40.30
Vested, weighted average grant date fair value (in dollars per share)		0
Forfeited, weighted average grant date fair value (in dollars per share)		16.62
Non-vested, weighted average grant date fair value, ending balance (in dollars per share)	$ 12.94	$ 12.94

Segment Information (Narrative) (Details)	9 Months Ended
Segment Information (Narrative) (Details)	Sep. 30, 2017 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Net sales to external customers	$ 1,584	$ 1,398	$ 4,608	$ 4,078
Adjusted EBITDA	381	268	1,028	583
Depreciation and amortization	62	73	204	212
Operating Segments [Member] \| Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	799	625	2,173	1,742
Adjusted EBITDA	249	144	601	309
Depreciation and amortization	24	32	89	87
Operating Segments [Member] \| Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	637	591	1,998	1,695
Adjusted EBITDA	158	143	510	333
Depreciation and amortization	28	26	81	75
Operating Segments [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	148	182	437	641
Adjusted EBITDA	18	9	37	30
Depreciation and amortization	4	6	13	24
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	0	0	0	0
Adjusted EBITDA	(44)	(28)	(120)	(89)
Depreciation and amortization	$ 6	$ 9	$ 21	$ 26

Segment Information (Reconciliation to Consolidated Income Statements) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting [Abstract]
Income before income taxes	$ 250	$ 234	$ 649	$ 262
Interest expense, net	55	51	161	157
Depreciation and amortization	62	73	204	212
Non-operating pension and other post-retirement employee benefit income	(7)	(5)	(24)	(19)
Exchange losses (gains)	4	17	(3)	37
Restructuring charges	8	14	31	41
Asset-related charges	1	46	3	109
Gain on sale of assets and businesses	0	(169)	(14)	(258)
Transaction costs	1	2	3	18
Legal and other charges	7	5	18	24
Adjusted EBITDA	$ 381	$ 268	$ 1,028	$ 583

Guarantor Condensed Consolidating Financial Information (Condensed Consolidated Statements of Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Income Statements, Captions [Line Items]
Net sales	$ 1,584	$ 1,398	$ 4,608	$ 4,078
Cost of goods sold	1,117	1,056	3,341	3,267
Gross profit	467	342	1,267	811
Selling, general and administrative expense	148	148	444	454
Research and development expense	20	19	61	60
Restructuring and asset-related charges, net	8	60	31	145
Total expenses	176	227	536	659
Equity in (loss) earnings of affiliates	9	9	26	17
Equity in earnings of subsidiaries		0	0	0
Interest (expense) income, net	(55)	(51)	(161)	(157)
Intercompany interest income (expense), net		0	0	0
Other income (expense), net	5	161	53	250
Income before income taxes	250	234	649	262
(Benefit from) provision for income taxes	43	30	130	25
Net income (loss)	207	204	519	237
Less: Net income attributable to non-controlling interests		0	1	0
Net income (loss) attributable to Chemours	207	204	518	237
Comprehensive income (loss) attributable to Chemours	228	210	675	250
Eliminations and Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Net sales	(429)	(410)	(1,237)	(1,187)
Cost of goods sold	(409)	(391)	(1,227)	(1,160)
Gross profit	(20)	(19)	(10)	(27)
Selling, general and administrative expense	(7)	(6)	(22)	(16)
Research and development expense		0	0	0
Restructuring and asset-related charges, net		0	0	0
Total expenses	(7)	(6)	(22)	(16)
Equity in (loss) earnings of affiliates		0	0	0
Equity in earnings of subsidiaries	(233)	(226)	(594)	(307)
Interest (expense) income, net		0	0	0
Intercompany interest income (expense), net		0	0	0
Other income (expense), net	(6)	(8)	(22)	(15)
Income before income taxes	(252)	(247)	(604)	(333)
(Benefit from) provision for income taxes	(1)	(15)	1	(10)
Net income (loss)	(251)	(232)	(605)	(323)
Less: Net income attributable to non-controlling interests		0	0	0
Net income (loss) attributable to Chemours	(251)	(232)	(605)	(323)
Comprehensive income (loss) attributable to Chemours	(288)	(244)	(818)	(345)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales		0	0	0
Cost of goods sold		0	0	0
Gross profit		0	0	0
Selling, general and administrative expense	7	5	26	17
Research and development expense		0	0	0
Restructuring and asset-related charges, net		0	0	0
Total expenses	7	5	26	17
Equity in (loss) earnings of affiliates		0	0	0
Equity in earnings of subsidiaries	233	226	594	307
Interest (expense) income, net	(57)	(50)	(164)	(155)
Intercompany interest income (expense), net	16	15	48	44
Other income (expense), net	6	5	19	15
Income before income taxes	191	191	471	194
(Benefit from) provision for income taxes	(16)	(13)	(47)	(43)
Net income (loss)	207	204	518	237
Less: Net income attributable to non-controlling interests		0	0	0
Net income (loss) attributable to Chemours	207	204	518	237
Comprehensive income (loss) attributable to Chemours	228	210	675	250
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales	960	961	2,904	2,898
Cost of goods sold	773	791	2,358	2,506
Gross profit	187	170	546	392
Selling, general and administrative expense	105	115	339	350
Research and development expense	19	19	57	58
Restructuring and asset-related charges, net	8	60	28	147
Total expenses	132	194	424	555
Equity in (loss) earnings of affiliates		1	0	(2)
Equity in earnings of subsidiaries		0	0	0
Interest (expense) income, net	2	(1)	1	(2)
Intercompany interest income (expense), net		1	0	4
Other income (expense), net	22	70	93	178
Income before income taxes	79	47	216	15
(Benefit from) provision for income taxes	18	29	40	25
Net income (loss)	61	18	176	(10)
Less: Net income attributable to non-controlling interests		0	0	0
Net income (loss) attributable to Chemours	61	18	176	(10)
Comprehensive income (loss) attributable to Chemours	63	18	178	(10)
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales	1,053	847	2,941	2,367
Cost of goods sold	753	656	2,210	1,921
Gross profit	300	191	731	446
Selling, general and administrative expense	43	34	101	103
Research and development expense	1	0	4	2
Restructuring and asset-related charges, net		0	3	(2)
Total expenses	44	34	108	103
Equity in (loss) earnings of affiliates	9	8	26	19
Equity in earnings of subsidiaries		0	0	0
Interest (expense) income, net		0	2	0
Intercompany interest income (expense), net	(16)	(16)	(48)	(48)
Other income (expense), net	(17)	94	(37)	72
Income before income taxes	232	243	566	386
(Benefit from) provision for income taxes	42	29	136	53
Net income (loss)	190	214	430	333
Less: Net income attributable to non-controlling interests		0	1	0
Net income (loss) attributable to Chemours	190	214	429	333
Comprehensive income (loss) attributable to Chemours	$ 225	$ 226	$ 640	$ 355

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheets) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,535	$ 902	$ 957	$ 366
Accounts and notes receivable - trade, net	942	807
Intercompany receivable	0	0
Inventories	877	767
Prepaid expenses and other	79	77
Deferred income taxes	0
Total current assets	3,433	2,553
Property, plant and equipment	8,412	7,997
Less: Accumulated depreciation	(5,462)	(5,213)
Property, plant and equipment, net	2,950	2,784
Goodwill and other intangible assets, net	167	170
Investments in affiliates	166	136
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Other assets	404	417
Total assets	7,120	6,060
Current liabilities:
Accounts payable	1,010	884
Current maturities of long-term debt	14	15
Intercompany payable	0	0
Other accrued liabilities	546	872
Total current liabilities	1,570	1,771
Long-term debt, net	4,081	3,529
Intercompany notes payable	0	0
Deferred income taxes	175	132
Other liabilities	489	524
Total liabilities	6,315	5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	800	100
Non-controlling interests	5	4
Total equity	805	104	381	130
Total liabilities and equity	7,120	6,060
Eliminations and Adjustments [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Accounts and notes receivable - trade, net	0	0
Intercompany receivable	(899)	(1,099)
Inventories	(63)	(50)
Prepaid expenses and other	0	7
Deferred income taxes	0
Total current assets	(962)	(1,142)
Property, plant and equipment	0	0
Less: Accumulated depreciation	0	0
Property, plant and equipment, net	0	0
Goodwill and other intangible assets, net	0	0
Investments in affiliates	0	0
Investment in subsidiaries	(4,114)	(3,258)
Intercompany notes receivable	(1,150)	(1,150)
Other assets	(24)	0
Total assets	(6,250)	(5,550)
Current liabilities:
Accounts payable	0	0
Current maturities of long-term debt	0	0
Intercompany payable	(899)	(1,099)
Other accrued liabilities	0	0
Total current liabilities	(899)	(1,099)
Long-term debt, net	0	0
Intercompany notes payable	(1,150)	(1,150)
Deferred income taxes	(24)	0
Other liabilities	0	0
Total liabilities	(2,073)	(2,249)
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	(4,177)	(3,301)
Non-controlling interests	0	0
Total equity	(4,177)	(3,301)
Total liabilities and equity	(6,250)	(5,550)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Accounts and notes receivable - trade, net	0	0
Intercompany receivable	19	3
Inventories	0	0
Prepaid expenses and other	0	0
Deferred income taxes	0
Total current assets	19	3
Property, plant and equipment	0	0
Less: Accumulated depreciation	0	0
Property, plant and equipment, net	0	0
Goodwill and other intangible assets, net	0	0
Investments in affiliates	0	0
Investment in subsidiaries	4,114	3,258
Intercompany notes receivable	1,150	1,150
Other assets	35	13
Total assets	5,318	4,424
Current liabilities:
Accounts payable	0	0
Current maturities of long-term debt	14	15
Intercompany payable	354	762
Other accrued liabilities	72	21
Total current liabilities	440	798
Long-term debt, net	4,078	3,526
Intercompany notes payable	0	0
Deferred income taxes	0	0
Other liabilities	0	0
Total liabilities	4,518	4,324
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	800	100
Non-controlling interests	0	0
Total equity	800	100
Total liabilities and equity	5,318	4,424
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	504	224	380	95
Accounts and notes receivable - trade, net	316	299
Intercompany receivable	684	1,050
Inventories	348	341
Prepaid expenses and other	59	38
Deferred income taxes	0
Total current assets	1,911	1,952
Property, plant and equipment	6,346	6,136
Less: Accumulated depreciation	(4,410)	(4,285)
Property, plant and equipment, net	1,936	1,851
Goodwill and other intangible assets, net	153	156
Investments in affiliates	0	0
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Other assets	101	178
Total assets	4,101	4,137
Current liabilities:
Accounts payable	589	573
Current maturities of long-term debt	0	0
Intercompany payable	196	46
Other accrued liabilities	310	718
Total current liabilities	1,095	1,337
Long-term debt, net	3	3
Intercompany notes payable	0	0
Deferred income taxes	107	59
Other liabilities	392	428
Total liabilities	1,597	1,827
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	2,504	2,310
Non-controlling interests	0	0
Total equity	2,504	2,310
Total liabilities and equity	4,101	4,137
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	1,031	678	$ 577	$ 271
Accounts and notes receivable - trade, net	626	508
Intercompany receivable	196	46
Inventories	592	476
Prepaid expenses and other	20	32
Deferred income taxes	0
Total current assets	2,465	1,740
Property, plant and equipment	2,066	1,861
Less: Accumulated depreciation	(1,052)	(928)
Property, plant and equipment, net	1,014	933
Goodwill and other intangible assets, net	14	14
Investments in affiliates	166	136
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Other assets	292	226
Total assets	3,951	3,049
Current liabilities:
Accounts payable	421	311
Current maturities of long-term debt	0	0
Intercompany payable	349	291
Other accrued liabilities	164	133
Total current liabilities	934	735
Long-term debt, net	0	0
Intercompany notes payable	1,150	1,150
Deferred income taxes	92	73
Other liabilities	97	96
Total liabilities	2,273	2,054
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	1,673	991
Non-controlling interests	5	4
Total equity	1,678	995
Total liabilities and equity	$ 3,951	$ 3,049

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Cash (used for) provided by operating activities	$ 336	$ 324
Investing activities
Purchases of property, plant and equipment	(246)	(235)
Proceeds from sales of assets and businesses, net	39	707
Intercompany investing activities	0	0
Foreign exchange contract settlements, net	5	(1)
Investment in affiliates	0	(2)
Cash (used for) provided by investing activities	(202)	469
Financing activities
Proceeds from issuance of debt, net	494	0
Intercompany short-term borrowing repayments, net	0	0
Debt repayments	(24)	(212)
Dividends paid	(16)	(16)
Deferred financing fees	(6)	(2)
Tax payments related to withholdings on vested restricted stock units	(10)	0
Proceeds from issuance of stock options, net	30	0
Cash provided by (used for) financing activities	468	(230)
Effect of exchange rate changes on cash and cash equivalents	31	28
Increase in cash and cash equivalents	633	591
Cash and cash equivalents at beginning of the period	902	366
Cash and cash equivalents at end of the period	1,535	957
Eliminations and Adjustments [Member]
Operating activities
Cash (used for) provided by operating activities	0	0
Investing activities
Purchases of property, plant and equipment	0	0
Proceeds from sales of assets and businesses, net	0	0
Intercompany investing activities	(408)	328
Foreign exchange contract settlements, net	0	0
Investment in affiliates		0
Cash (used for) provided by investing activities	(408)	328
Financing activities
Proceeds from issuance of debt, net	0
Intercompany short-term borrowing repayments, net	408	(328)
Debt repayments	0	0
Dividends paid	0	0
Deferred financing fees	0	0
Tax payments related to withholdings on vested restricted stock units	0
Proceeds from issuance of stock options, net	0
Cash provided by (used for) financing activities	408	(328)
Effect of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of the period	0	0
Cash and cash equivalents at end of the period	0	0
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Operating activities
Cash (used for) provided by operating activities	(60)	(105)
Investing activities
Purchases of property, plant and equipment	0	0
Proceeds from sales of assets and businesses, net	0	0
Intercompany investing activities	0	0
Foreign exchange contract settlements, net	0	0
Investment in affiliates		0
Cash (used for) provided by investing activities	0	0
Financing activities
Proceeds from issuance of debt, net	494
Intercompany short-term borrowing repayments, net	(408)	328
Debt repayments	(24)	(205)
Dividends paid	(16)	(16)
Deferred financing fees	(6)	(2)
Tax payments related to withholdings on vested restricted stock units	(10)
Proceeds from issuance of stock options, net	30
Cash provided by (used for) financing activities	60	105
Effect of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of the period	0	0
Cash and cash equivalents at end of the period	0	0
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Operating activities
Cash (used for) provided by operating activities	32	173
Investing activities
Purchases of property, plant and equipment	(204)	(142)
Proceeds from sales of assets and businesses, net	39	590
Intercompany investing activities	408	(328)
Foreign exchange contract settlements, net	5	(1)
Investment in affiliates		0
Cash (used for) provided by investing activities	248	119
Financing activities
Proceeds from issuance of debt, net	0
Intercompany short-term borrowing repayments, net	0	0
Debt repayments	0	(7)
Dividends paid	0	0
Deferred financing fees	0	0
Tax payments related to withholdings on vested restricted stock units	0
Proceeds from issuance of stock options, net	0
Cash provided by (used for) financing activities	0	(7)
Effect of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	280	285
Cash and cash equivalents at beginning of the period	224	95
Cash and cash equivalents at end of the period	504	380
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Operating activities
Cash (used for) provided by operating activities	364	256
Investing activities
Purchases of property, plant and equipment	(42)	(93)
Proceeds from sales of assets and businesses, net	0	117
Intercompany investing activities	0	0
Foreign exchange contract settlements, net	0	0
Investment in affiliates		(2)
Cash (used for) provided by investing activities	(42)	22
Financing activities
Proceeds from issuance of debt, net	0
Intercompany short-term borrowing repayments, net	0	0
Debt repayments	0	0
Dividends paid	0	0
Deferred financing fees	0	0
Tax payments related to withholdings on vested restricted stock units	0
Proceeds from issuance of stock options, net	0
Cash provided by (used for) financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	31	28
Increase in cash and cash equivalents	353	306
Cash and cash equivalents at beginning of the period	678	271
Cash and cash equivalents at end of the period	$ 1,031	$ 577